Drug combinations and their uses
By using the combination of inhibitors such as Notch signaling pathway and ascorbic acid, the problems of toxic and side effects of chemotherapy drugs and insensitivity are solved, and effective inhibition and safe treatment effects on malignant tumors are achieved.
Patent Information
- Application Number
- CN202180023639.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-03-31
- Filing Date
- 2021-03-30
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-03-30
AI Technical Summary
Existing chemotherapeutic drugs have serious toxic side effects when treating malignant tumors, and some tumor patients are not sensitive to these drugs, resulting in unsatisfactory treatment results.
Use a combination of drug combinations containing Notch signaling pathway inhibitors, HH signaling pathway inhibitors, Porcupine inhibitors, RXRα inhibitors, Niclosamide, CK1a inhibitors and Frizzled receptor inhibitors in combination with ascorbic acid or its derivatives for alternative or combination with traditional Chemotherapy drugs to reduce toxic side effects and improve treatment effects.
This drug combination significantly reduces the growth of tumor cells, reduces the dose demand of traditional chemotherapy drugs, reduces toxic side effects, improves drug safety, and has a therapeutic effect on tumor patients who are insensitive to traditional chemotherapy drugs.
Smart Images

Figure HSB0000206692860000011 
Figure HSB0000206692860000012 
Figure HSB0000206692860000021
Abstract
Description
Technical Field
[0001] The present application relates to the field of biomedicine, and specifically to a drug combination and its use. Background Art
[0002] Malignant tumors are currently serious diseases that endanger human health. For example, osteosarcoma is a common malignant bone tumor with an annual incidence of about 3 / 1 million in China. Usually, 20% of patients have already developed distant metastasis when osteosarcoma is diagnosed. If osteosarcoma has distant metastasis, the patient's five-year disease-free survival rate is less than 20%. The drugs currently used to treat osteosarcoma are high-dose methotrexate, ifosfamide, doxorubicin, cisplatin, etc., or two or more drugs are used in combination for chemotherapy and sufficient dose intensity. These chemotherapy methods will have strong side effects that endanger life and health; colorectal cancer accounts for 20% of the total cases. Colorectal cancer accounts for 10.2% of the total number of cancer cases and 9.2% of the total number of deaths, that is, there are about 1.85 million new cases and 880,000 deaths each year. Oxaliplatin is the main treatment for colorectal cancer, but more than 30% of colon cancer patients are insensitive to oxaliplatin; the incidence of ovarian cancer accounts for about 3.4% of malignant tumors. Clinical chemotherapy regimens include platinum drugs + cyclophosphamide (PC), and taxol + carboplatin (TP), but these chemotherapy regimens also have serious side effects, such as damage to the digestive system and blood system. All these indicate that chemotherapy drugs also show different degrees of toxic side effects while fighting tumors, and some tumor patients are insensitive to chemotherapy drugs. Therefore, finding more effective anti-tumor drugs and methods is a problem that the medical community around the world urgently needs to solve. Summary of the invention
[0003] The present application provides a drug combination and its use or administration method, which mainly comprises a therapeutic agent comprising a Notch signaling pathway inhibitor, an HH signaling pathway inhibitor, a Porcupine inhibitor, an RXRα inhibitor, a Niclosamide, a CK1a inhibitor and / or a Frizzled receptor inhibitor and ascorbic acid or its derivatives as a drug combination for treating tumors, or a therapeutic agent comprising a Notch signaling pathway inhibitor, an HH signaling pathway inhibitor, an RXRα inhibitor and / or a Wnt signaling pathway inhibitor and ascorbic acid or its derivatives are administered in combination to treat tumors, having at least one of the following technical effects:
[0004] 1) The drug combination can be used as an alternative therapy to traditional chemotherapy drugs to avoid the toxic side effects of traditional chemotherapy on the human body.
[0005] 2) The drug combination is used to treat cancer patients who are insensitive to traditional chemotherapy drugs to achieve therapeutic effects.
[0006] 3) The drug combination can be used in conjunction with traditional chemotherapy drugs to reduce the dosage of chemotherapy drugs, thereby reducing the toxic side effects of traditional chemotherapy drugs.
[0007] 4) The combination of drugs achieved an unexpected inhibitory effect on tumors, significantly reduced the dosage of a single drug with the same effect, and improved the safety of medication.
[0008] 5) The drug combination specifically inhibits tumor cell growth and has no effect on other normal cells (such as 293 cells), which reflects the safety of the drug.
[0009] The present application provides a drug combination comprising:
[0010] a) a preventive and / or therapeutically effective amount of ascorbic acid or a derivative thereof; and
[0011] b) a preventively and / or therapeutically effective amount of a second therapeutic agent selected from the group consisting of a Notch signaling pathway inhibitor, an HH signaling pathway inhibitor, a Porcupine inhibitor, a RXRα inhibitor, Niclosamide, a CK1a inhibitor and a Frizzled receptor inhibitor.
[0012] In certain embodiments, the RXRα inhibitor comprises berberine or a pharmaceutically acceptable salt thereof.
[0013] In certain embodiments, the Notch signaling pathway inhibitor comprises a γ-secretase inhibitor.
[0014] In certain embodiments, the γ-secretase inhibitor comprises MK0752, RO4929097 and / or PF-03084014.
[0015] In certain embodiments, the HH signaling pathway inhibitor comprises a SMO inhibitor.
[0016] In certain embodiments, the SMO inhibitor comprises Vismodegib, Sonidegib and / or Glasdegib.
[0017] In certain embodiments, the porcupine inhibitor comprises LGK974 and / or ETC-159.
[0018] In certain embodiments, the CK1a inhibitor comprises Pyrvinium.
[0019] In certain embodiments, the Frizzled receptor inhibitor comprises Foxy-5.
[0020] In certain embodiments, the inhibitor comprises Fervenulin, 3-Methyltoxoflavin and / or Walrycin B.
[0021] In certain embodiments, the ascorbic acid derivative comprises a pharmaceutically acceptable ascorbate salt.
[0022] In certain embodiments, the pharmaceutically acceptable ascorbate comprises sodium ascorbate.
[0023] In certain embodiments, the ratio of the effective amount of the second therapeutic agent to the effective amount of ascorbic acid or a derivative thereof is from about 1:10 to about 1:5000.
[0024] In certain embodiments, the mass ratio of the second therapeutic agent to the ascorbic acid or a derivative thereof is from about 1:10 to about 1:5000.
[0025] In certain embodiments, the second therapeutic agent and the ascorbic acid or a derivative thereof are each present in different containers.
[0026] In certain embodiments, the pharmaceutical combination comprises a first formulation and a second formulation, wherein the first formulation comprises the ascorbic acid or a derivative thereof and a first pharmaceutically acceptable carrier, and the second formulation comprises the second therapeutic agent and a second pharmaceutically acceptable carrier.
[0027] In certain embodiments, the pharmaceutical combination comprises a pharmaceutical composition, and the pharmaceutical composition comprises the second therapeutic agent and the ascorbic acid or a derivative thereof.
[0028] In certain embodiments, the second therapeutic agent is present in the pharmaceutical composition in an amount of about 5% to about 20% (w / w).
[0029] In certain embodiments, the content of ascorbic acid or its derivatives in the pharmaceutical composition is about 80% to about 95% (w / w).
[0030] On the other hand, the present application also provides a kit, which includes the drug combination described in the present application.
[0031] On the other hand, the present application also provides the use of a combination of ascorbic acid or its derivatives and a second therapeutic agent in the preparation of a medicament for preventing and / or treating tumors, wherein the second therapeutic agent is selected from: Notch signaling pathway inhibitors, HH signaling pathway inhibitors, RXRα inhibitors and Wnt signaling pathway inhibitors.
[0032] In certain embodiments, the Wnt signaling pathway inhibitor comprises a Porcupine inhibitor, a Dvl-2 inhibitor, a CK1a inhibitor and / or a Frizzled receptor inhibitor.
[0033] In certain embodiments, the porcupine inhibitor comprises LGK974 and / or ETC-159.
[0034] In certain embodiments, the Dvl-2 inhibitor comprises Niclosamide and / or Sulindac.
[0035] In certain embodiments, the CK1a inhibitor comprises Pyrvinium.
[0036] In certain embodiments, the Frizzled receptor inhibitor comprises Foxy-5.
[0037] In certain embodiments, the RXRα inhibitor comprises berberine or a pharmaceutically acceptable salt thereof.
[0038] In certain embodiments, the Notch signaling pathway inhibitor comprises a γ-secretase inhibitor.
[0039] In certain embodiments, the γ-secretase inhibitor comprises MK0752, RO4929097 and / or PF-03084014.
[0040] In certain embodiments, the HH signaling pathway inhibitor comprises a SMO inhibitor.
[0041] In certain embodiments, the SMO inhibitor comprises Vismodegib, Sonidegib and / or Glasdegib.
[0042] In certain embodiments, the tumor comprises a solid tumor and a non-solid tumor.
[0043] In certain embodiments, the solid tumor comprises osteosarcoma and / or colon cancer.
[0044] In certain embodiments, the non-solid tumor comprises a lymphoma.
[0045] In certain embodiments, the ascorbic acid derivative comprises a pharmaceutically acceptable ascorbate salt.
[0046] In certain embodiments, the pharmaceutically acceptable ascorbate comprises sodium ascorbate.
[0047] In certain embodiments, the second therapeutic agent and the ascorbic acid or a derivative thereof are configured to be administered to the subject simultaneously.
[0048] In certain embodiments, the second therapeutic agent and the ascorbic acid or a derivative thereof are formulated to be administered separately to the subject.
[0049] In certain embodiments, the medicament is formulated such that the second therapeutic agent is administered at a dose of about 1 mg / kg to about 100 mg / kg.
[0050] In certain embodiments, the medicament is formulated such that the ascorbic acid or a derivative thereof is administered at a dose of about 0.05 g / kg to about 2.5 g / kg.
[0051] In certain embodiments, the medicament is formulated such that the second therapeutic agent and the ascorbic acid or a derivative thereof are administered in a mass ratio of about 1:5 to about 1:5000.
[0052] In certain embodiments, the medicament is formulated such that the second therapeutic agent and the ascorbic acid or a derivative thereof are administered in a mass ratio of about 1:5 to about 1:5000.
[0053] On the other hand, the present application also provides a method for preventing and / or treating tumors, comprising administering to a subject in need thereof:
[0054] a) ascorbic acid or its derivatives; and
[0055] b) a second therapeutic agent, wherein the second therapeutic agent is selected from: a Notch signaling pathway inhibitor, an HH signaling pathway inhibitor, a RXRα inhibitor and a Wnt signaling pathway inhibitor.
[0056] In certain embodiments, the Wnt signaling pathway inhibitor comprises a Porcupine inhibitor, a Dvl-2 inhibitor, a CK1a inhibitor and / or a Frizzled receptor inhibitor.
[0057] In certain embodiments, the porcupine inhibitor comprises LGK974 and / or ETC-159.
[0058] In certain embodiments, the Dvl-2 inhibitor comprises Niclosamide and / or Sulindac.
[0059] In certain embodiments, the CK1a inhibitor comprises Pyrvinium.
[0060] In certain embodiments, the Frizzled receptor inhibitor comprises Foxy-5.
[0061] In certain embodiments, the RXRα inhibitor comprises berberine or a pharmaceutically acceptable salt thereof.
[0062] In certain embodiments, the Notch signaling pathway inhibitor comprises a γ-secretase inhibitor.
[0063] In certain embodiments, the γ-secretase inhibitor comprises MK0752, RO4929097 and / or PF-03084014.
[0064] In certain embodiments, the HH signaling pathway inhibitor comprises a SMO inhibitor.
[0065] In certain embodiments, the SMO inhibitor comprises Vismodegib, Sonidegib and / or Glasdegib.
[0066] In certain embodiments, the tumor comprises a solid tumor and a non-solid tumor.
[0067] In certain embodiments, the solid tumor comprises osteosarcoma and / or colon cancer.
[0068] In certain embodiments, the non-solid tumor comprises a lymphoma.
[0069] In certain embodiments, the ascorbic acid derivative comprises a pharmaceutically acceptable ascorbate salt.
[0070] In certain embodiments, the pharmaceutically acceptable ascorbate comprises sodium ascorbate.
[0071] In certain embodiments, the second therapeutic agent and the ascorbic acid or a derivative thereof are configured to be administered to the subject simultaneously.
[0072] In certain embodiments, the second therapeutic agent and the ascorbic acid or a derivative thereof are formulated to be administered separately to the subject.
[0073] In certain embodiments, the medicament is formulated such that the second therapeutic agent is administered at a dose of about 1 mg / kg to about 100 mg / kg.
[0074] In certain embodiments, the medicament is formulated such that the ascorbic acid or a derivative thereof is administered at a dose of about 0.05 g / kg to about 2.5 g / kg.
[0075] In certain embodiments, the medicament is formulated such that the second therapeutic agent and the ascorbic acid or a derivative thereof are administered in a mass ratio of about 1:5 to about 1:5000.
[0076] In certain embodiments, the medicament is formulated such that the second therapeutic agent and the ascorbic acid or a derivative thereof are administered in a mass ratio of about 1:5 to about 1:5000.
[0077] On the other hand, the present application also provides a method for monitoring a subject's response to a drug, the method comprising:
[0078] a) administering ascorbic acid or a derivative thereof and a second therapeutic agent to the subject, wherein the second therapeutic agent is selected from the group consisting of: a Notch signaling pathway inhibitor, an HH signaling pathway inhibitor, a RXRα inhibitor, and a Wnt signaling pathway inhibitor; and
[0079] b) detecting one or more of the following changes in the subject after the administration of a): blood alkaline phosphatase level and / or activity, lactate dehydrogenase level and / or activity, CADM1 gene expression level, CD44 gene expression level, livin gene expression level, HIF-1α gene expression level, ET-1 gene expression level, IGF-1R gene expression level, STAT3 gene expression level, CEA gene expression level, CA199 gene expression level, CA125 gene expression level, AFP gene expression level, CA724 gene expression level, β-HCG gene expression level.
[0080] In certain embodiments, the Wnt signaling pathway inhibitor comprises a Porcupine inhibitor, a Dvl-2 inhibitor, a CK1a inhibitor and / or a Frizzled receptor inhibitor.
[0081] In certain embodiments, the porcupine inhibitor comprises LGK974 and / or ETC-159.
[0082] In certain embodiments, the Dvl-2 inhibitor comprises Niclosamide and / or Sulindac.
[0083] In certain embodiments, the CK1a inhibitor comprises Pyrvinium.
[0084] In certain embodiments, the Frizzled receptor inhibitor comprises Foxy-5.
[0085] In certain embodiments, the RXRα inhibitor comprises berberine or a pharmaceutically acceptable salt thereof.
[0086] In certain embodiments, the Notch signaling pathway inhibitor comprises a γ-secretase inhibitor.
[0087] In certain embodiments, the γ-secretase inhibitor comprises MK0752, RO4929097 and / or PF-03084014.
[0088] In certain embodiments, the HH signaling pathway inhibitor comprises a SMO inhibitor.
[0089] In certain embodiments, the SMO inhibitor comprises Vismodegib, Sonidegib and / or Glasdegib.
[0090] In certain embodiments, the tumor comprises a solid tumor and a non-solid tumor.
[0091] In certain embodiments, the solid tumor comprises osteosarcoma and / or colon cancer.
[0092] In certain embodiments, the non-solid tumor comprises a lymphoma.
[0093] In certain embodiments, the ascorbic acid derivative comprises a pharmaceutically acceptable ascorbate salt.
[0094] In certain embodiments, the pharmaceutically acceptable ascorbate comprises sodium ascorbate.
[0095] In certain embodiments, the second therapeutic agent and the ascorbic acid or a derivative thereof are configured to be administered to the subject simultaneously.
[0096] In certain embodiments, the second therapeutic agent and the ascorbic acid or a derivative thereof are formulated to be administered separately to the subject.
[0097] In certain embodiments, the medicament is formulated such that the second therapeutic agent is administered at a dose of about 1 mg / kg to about 100 mg / kg.
[0098] In certain embodiments, the medicament is formulated such that the ascorbic acid or a derivative thereof is administered at a dose of about 0.05 g / kg to about 2.5 g / kg.
[0099] In certain embodiments, the medicament is formulated such that the second therapeutic agent and the ascorbic acid or a derivative thereof are administered in a mass ratio of about 1:5 to about 1:5000.
[0100] In certain embodiments, the medicament is formulated such that the second therapeutic agent and the ascorbic acid or a derivative thereof are administered in a mass ratio of about 1:5 to about 1:5000.
[0101] Those skilled in the art can easily perceive other aspects and advantages of the present application from the detailed description below. In the detailed description below, only exemplary embodiments of the present application are shown and described. As will be appreciated by those skilled in the art, the content of the present application enables those skilled in the art to modify the disclosed specific embodiments without departing from the spirit and scope of the invention to which the present application relates. Accordingly, the description in the drawings and specification of the present application is merely exemplary and not restrictive. BRIEF DESCRIPTION OF THE DRAWINGS
[0102] The specific features of the invention involved in this application are shown in the attached claims. The features and advantages of the invention involved in this application can be better understood by referring to the exemplary embodiments and drawings described in detail below. A brief description of the drawings is as follows:
[0103] Figure 1 Shown are the effects of different concentrations of berberine on 143B cells and HOS cells as described in the present application.
[0104] Figure 2 Shown is the inhibitory effect of berberine combined with sodium ascorbate described in the present application on 143B cells and HOS cells.
[0105] Figure 3 Shown are the effects of different concentrations of Foxy-5 described in this application on 143B cells and HOS cells.
[0106] Figure 4 Shown is the inhibitory effect of Foxy-5 combined with sodium ascorbate described in the present application on 143B cells and HOS cells.
[0107] Figure 5 Shown is the inhibitory effect of Pyrvinium combined with sodium ascorbate described in the present application on 143B cells and HOS cells.
[0108] Figure 6 Shown is the inhibitory effect of Niclosamide combined with sodium ascorbate described in the present application on 143B cells and HOS cells.
[0109] Figure 7 Shown is the inhibitory effect of ETC-159 described in the present application in combination with sodium ascorbate on 143B cells and HOS cells.
[0110] Figure 8 Shown is the inhibitory effect of LGK974 described in the present application in combination with sodium ascorbate on 143B cells and HOS cells.
[0111] Fig. 9Shown are the effects of various concentrations of Sonidegib described herein on 143B cells and HOS cells.
[0112] Fig.10 Shown is the inhibitory effect of Sonidegib combined with sodium ascorbate described in the present application on 143B cells and HOS cells.
[0113] Fig.11 Shown is the inhibitory effect of Vismodegib combined with sodium ascorbate described in the present application on 143B cells and HOS cells.
[0114] Fig.12 Shown are the effects of different concentrations of PF-03084014 described herein on 143B cells and HOS cells.
[0115] Fig.13 Shown is the inhibitory effect of PF-03084014 described in the present application combined with sodium ascorbate on 143B cells and HOS cells.
[0116] Fig.14 Shown is the inhibitory effect of RO4929097 combined with sodium ascorbate described in the present application on 143B cells and HOS cells.
[0117] Fig.15 Shown is the inhibitory effect of MK0752 combined with sodium ascorbate described in the present application on 143B cells and HOS cells.
[0118] Fig.16 Shown are the effects of different concentrations of Sulindac described in this application on 143B cells and HOS cells.
[0119] Fig.17 Shown is the inhibitory effect of Sulindac combined with sodium ascorbate described in the present application on 143B cells and HOS cells.
[0120] Fig.18 Shown is the inhibitory effect of Niclosamide combined with sodium ascorbate described in the present application on MC38 cells.
[0121] Fig.19 Shown is the inhibitory effect of different concentrations of Niclosamide combined with sodium ascorbate on DB cells as described in the present application. DETAILED DESCRIPTION
[0122] The following is an explanation of the implementation of the present invention by means of specific embodiments. Those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.
[0123] Definition of terms
[0124] In this application, the term "Notch signaling pathway" generally refers to the cell signaling pathway mediated by the Notch receptor. The Notch signaling pathway is a highly conserved cell signal transduction system present in most multicellular organisms. The Notch signaling pathway is mainly composed of Notch receptors, Notch ligands (DSL proteins), CSL (a collective name for CBF-1, Su(H), and Lag) DNA binding proteins, Notch regulatory molecules, and other effectors. CBF-1, Su(H), and Lag1 are different names for this protein in mammals, fruit flies, and nematodes. In 1917, Morgan and his colleagues discovered the Notch gene in mutant fruit flies, and it was named because the partial functional loss of this gene would cause a notch (Notch) on the edge of the fruit fly's wings. Mammals have 4 Notch receptors (Notch1, Notch2, Notch3, Notch4) and 5 Notch ligands (Delta-like 1, Delta-like 3, Delta-like 4, Jagged1, and Jagged2). Studies have shown that the generation of Notch signals can be achieved through the interaction of Notch ligands and receptors of adjacent cells. The Notch protein undergoes three cleavages (such as cleavage mediated by γ-secretase) and is released into the cytoplasm from the intracellular segment (NICD), and enters the cell nucleus to bind to the transcription factor CSL to form a NICD / CSL transcription activation complex, thereby activating target genes of the basic helix-loop-helix (bHLH) transcription repressor family, such as HES, HEY, and HERP, and exerting biological effects.
[0125] In the present application, the term "functional variant" generally refers to a molecule that can include amino acid modifications (e.g., group substitutions, etc.) or insertions, substitutions, and / or deletions of one or more amino acids in the original protein sequence, while retaining the original sequence function. For example, the functional variant can have better biological activity (function) than the original sequence. For example, the retention does not have to be completely retained. For example, the functional variant can retain the original sequence function substantially, for example, retaining at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the original sequence function.
[0126] In this application, "γ-secretase" generally refers to an intramembrane proteolytic enzyme composed of four subunits that can cleave transmembrane proteins at residues within the transmembrane domain. The γ-secretase complex is generally composed of four separate protein subunits or their functional variants: presenilin-1, nicastrin, APH-1 and presenilin enhancer 2. Nicastrin's main role may be to maintain the stability of the complex and regulate the trafficking of intracellular proteins; PEN-2 associates with the complex by binding to the transmembrane domain of presenilin. Among other possible roles, PEN-2 helps stabilize the complex after presenilin proteolysis produces activated N-terminal and C-terminal fragments; APH-1 is required for proteolytic activity. It binds to the complex through a conserved α-helical interaction motif and helps to initiate the assembly of immature components. Gamma secretase is involved in the processing of beta-amyloid precursor protein (APP) and several other type I membrane proteins such as Notch, ErbB4, E-cadherin, N-cadherin, ephrin-B2 and / or CD44. Presenilin as the catalytic subunit is an aspartyl protease.
[0127] In this application, the term "HH signaling pathway" generally refers to a cell signaling pathway mediated by the Hedgeho (Hh) signaling molecule. In many developmental processes of vertebrates and invertebrates, the Hedgehog signaling pathway controls cell proliferation and differentiation. When the signaling pathway is abnormally activated, it may cause the occurrence and development of tumors. The Hedgehog signaling molecule is a localized protein ligand secreted by signaling cells. There are three Hedgehog homologous genes in mammals: Sonic Hedgehog (SHH), Indian Hedgehog (IHH) and Desert Hedgehog (DHH), which encode Shh, Ihh and Dhh proteins, respectively. Members of the Hh protein family are composed of two domains: the amino-terminal domain (Hh-N) and the carboxyl-terminal domain (Hh-C), of which Hh-N has the signaling activity of the Hh protein, while Hh-C has its own proteolytic enzyme activity and cholesterol transferase function. Hh signaling is controlled by two receptors on the target cell membrane, Patched (Ptc) and Smoothened (Smo). The receptor Ptc is encoded by the tumor suppressor gene Patched and is composed of a single peptide chain with 12 transmembrane regions. It can directly bind to the ligand and play a negative regulatory role in Hh signaling; Smo is the receptor required for Hedgeho (Hh) signal transduction.
[0128] In this application, the term "SMO" generally refers to the receptor or its functional variant required for Hedgeho (Hh) signaling in the HH signaling pathway. The receptor Smo is encoded by the proto-oncogene Smothened, is homologous to the G protein-coupled receptor, and is composed of a single peptide chain with 7 transmembrane regions. The N-terminus is located outside the cell, and the C-terminus is located inside the cell. The amino acid sequence of the transmembrane region is highly conserved. The serine and threonine residues at the C-terminus are phosphorylation sites, and bind to the phosphate group during protein kinase catalysis. This protein family member only has the function of a transcription promoter when the full length is maintained, initiating the transcription of downstream target genes; when the carboxyl terminus is hydrolyzed by the proteasome, a transcription repressor is formed to inhibit the transcription of downstream target genes. It has been reported that in the absence of Hh and Ptc, activation of Smo may lead to the activation of Hh target genes; when the gene Smo mutates, the same symptoms as the Hh gene mutation may appear.
[0129] In the present application, the term "Wnt signaling pathway" generally refers to a cell signaling pathway mediated by a Wnt protein. Three Wnt signaling pathways have now been identified: the canonical Wnt pathway, the noncanonical Wnt / planar cell polarity pathway (PCP) and the noncanonical Wnt / calcium pathway. All three Wnt signaling pathways are activated by the binding of Wnt protein ligands to their receptors, the Frizzled receptors. It is reported that the canonical Wnt signaling pathway can participate in the regulation of gene expression, the noncanonical planar cell polarization pathway can regulate the cytoskeleton to control cell shape, and the noncanonical Wnt / calcium pathway can regulate the concentration of intracellular calcium ions. The Wnt signaling pathway is often used for communication between adjacent cells (paracrine) or communication with the same cell itself (autocrine). The Wnt signaling pathway is highly conserved in animals.
[0130] In this application, the term "Dvl-2" generally refers to a member of the dishevelled (dsh) protein family or a functional variant thereof. In humans, the Dvl-2 protein is encoded by the DVL2 gene. The gene encodes a 90 kD protein that is post-translationally phosphorylated to form a 95 kD cytoplasmic protein that may play a role in a variety of Wnt protein-mediated signal transduction pathways. The vertebrate dsh protein has about 40% amino acid sequence similarity to Drosophila dsh.
[0131] In the present application, the term "drug combination" generally refers to a combination of at least two active ingredients / therapeutic agents. In some embodiments, each active ingredient / therapeutic agent can be prepared into an independent preparation (solid, liquid, gel, etc.), in some embodiments, each active ingredient / therapeutic agent can be present in different containers, and can also be formulated into a desired preparation with a suitable carrier simultaneously or separately when necessary; in some embodiments, each active ingredient / therapeutic agent can be from different sources (e.g., prepared, produced or sold by different merchants); in some embodiments, each active ingredient / therapeutic agent can form a pharmaceutical composition in a mixed form.
[0132] In the present application, the term "CK1a" is also referred to as "casein kinase 1α", which generally refers to a member of the casein kinase 1 family (EC2.7.11.1) or a functional variant thereof, and is a serine / threonine kinase (which also phosphorylates tyrosine residues in some cases). As its isoforms in mammals, casein kinase 1 is known to have seven types: α, β1, γ1, γ2, γ3, δ and ε. These isoforms are known to participate in the regulation of various biological functions by phosphorylating various substrate proteins, thereby activating or inactivating, stabilizing or destabilizing the functions of the proteins. The gene encoding casein kinase 1α can be found in HGNC: 2451.
[0133] In this application, the term "Frizzled receptor" is also referred to as "Frizzled receptor", which generally refers to a family of G protein-coupled receptors or their functional variants, which can serve as receptors in the Wnt signaling pathway and other signaling pathways. Generally, when it is activated, it can cause the activation of downstream proteins in the intracellular signaling pathway (e.g., Dishevelled). Frizzled receptor proteins generally contain a cysteine-rich domain, which is commonly found in proteins such as receptor tyrosine kinases. In humans, Frizzled receptors can include eight members of Frizzled receptors 1-8.
[0134] In this application, the term "Porcupine" generally refers to a protein or a functional variant thereof that can participate in secretion or endoplasmic reticulum transport in humans, which participates in Wnt signaling pathway conduction. In Caenorhabditis elegans, its homolog mom-1 has a similar function in promoting the secretion of Wnt protein Mom-2. Porcupine has certain homology with the o-acyltransferase family and may be involved in the modification of Wnt proteins. Its encoding gene can be found in HGNC: 17652.
[0135] In the present application, the term "RXRα" also known as NR2B1 (nuclear receptor subfamily 2, group B, member 1) generally refers to a nuclear receptor or a functional variant thereof. In humans, it is encoded by the RXRA gene, and the coding sequence can be found in MGI:98214.
[0136] In this application, the term "pharmaceutical composition" generally refers to a mixture comprising at least two active ingredients that are administered to a subject to treat a specific disease or condition affecting the individual. It allows the active ingredients to be in an effective form and does not contain additional components that are unacceptably toxic to the subject to which the composition is to be administered. Such a composition may be sterile and may also contain a pharmaceutically acceptable carrier.
[0137] In the present application, the term "inhibitor" generally refers to a compound / substance or composition that can completely or partially hinder or reduce the physiological function of one or more specific biomolecules (e.g., proteins, polypeptides, lipopolysaccharides, glycoproteins, ribonucleoprotein complexes, etc.). The physiological function of reducing one or more specific proteins can include a reduction in the activity of the protein itself (e.g., the ability to bind to other molecules, etc.) or a reduction in the amount of the protein itself. In some embodiments, the inhibitor can exist as different crystals, amorphous substances, pharmaceutically acceptable salts, hydrates, and solvates. In some embodiments, the inhibitor can hinder the activation of cell signaling pathways.
[0138] In the present application, the term "ascorbic acid derivative" generally refers to a compound that releases ascorbic acid (vitamin C) in vivo or in vitro and its solvates, hydrates and salts. The term also includes ascorbic acid analogs, wherein one or more hydroxyl groups of ascorbic acid are replaced by another structural part, and wherein the ascorbic acid analogs substantially retain the stable activity of ascorbic acid in vitro or in vivo.
[0139] In the present application, the term "effective amount" or "effective dose" generally refers to an amount sufficient to achieve or at least partially achieve the desired effect. A "therapeutically effective amount" or "therapeutically effective dose" of a drug or therapeutic agent is generally any amount of a drug that promotes disease regression (which is demonstrated by a reduction in the severity of disease symptoms, an increase in the frequency and duration of the disease asymptomatic period, or the prevention of damage or disability caused by suffering from the disease) when used alone or in combination with another therapeutic agent. A "preventive effective amount" or "preventive effective dose" of a drug generally refers to an amount of a drug that inhibits the development or recurrence of a disease when administered alone or in combination with another therapeutic agent to a subject at risk of disease development or disease recurrence. The ability of a therapeutic agent or preventive agent to promote disease regression or inhibit disease development or recurrence can be evaluated using a variety of methods known to those skilled in the art, such as in human subjects during clinical trials, predicting efficacy in humans in animal model systems, or by measuring the activity of a drug in an in vitro assay.
[0140] In this application, the term "prevention" generally refers to the prophylactic administration of a combination to healthy subjects to prevent the occurrence of a certain disease or condition. It can also include the prophylactic administration of a combination to a patient in the pre-stage of an allergic disease to be treated. "Prevention" does not require 100% elimination of the possibility of the disease or condition occurring. In other words, "prevention" generally refers to a reduction in the possibility or degree of occurrence of a disease or condition in the presence of the administration of the combination.
[0141] In this application, the term "treatment" generally refers to clinical intervention used to change the natural course of the treated individual or cell in the clinical pathological process. It may include improving the disease state, eliminating the lesion or improving the prognosis.
[0142] In the present application, the term "administer" generally refers to introducing the drug combination into the body of a subject by any introduction or delivery route. Any method known to those skilled in the art for contacting cells, organs or tissues with the drug combination can be used. Including but not limited to intra-arterial, intranasal, intraperitoneal, intravenous, intramuscular, subcutaneous transdermal or oral. The daily dose can be divided into one, two or more dosages of suitable form to be administered at one, two or more times during a certain time period.
[0143] In the present application, the term "tumor" generally refers to a vegetation or a solid lesion formed by abnormal cell growth. In the present application, a tumor can be a solid tumor or a non-solid tumor. In some embodiments, a tangible mass that can be touched by clinical examination such as x-ray film, CT scan, B-ultrasound or palpation can be called a solid tumor, and a tumor such as leukemia that cannot be seen or touched by X-ray, CT scan, B-ultrasound and palpation can be called a non-solid tumor.
[0144] In this application, the term "subject" generally refers to a human or non-human animal, including but not limited to cats, dogs, horses, pigs, cows, sheep, rabbits, mice, rats or monkeys.
[0145] In this application, the term "preparation", which may also be referred to as a pharmaceutical preparation, generally refers to a drug that is prepared according to certain dosage form requirements and can be provided to a subject for use in order to meet the needs of treatment or prevention. For example, a preparation may include an active ingredient and a carrier.
[0146] In this application, the term "carrier" generally refers to any substance other than the active ingredient. For example, a pharmaceutically acceptable substance, composition or vehicle for carrying or transporting a chemical agent. For example, a buffer, a surfactant, a stabilizer, a preservative, an absorption promoter for enhancing bioavailability, a liquid or solid filler, a diluent, an excipient, a solvent, an encapsulating material and / or other conventional solubilizing agents or dispersants, etc.
[0147] In this application, the term "container" generally refers to any vessel or device suitable for containing a drug, such as a medicine box, a medicine bottle, a medicine bag, a blister, a tube, a syringe, etc.
[0148] In this application, the terms "comprises" or "comprising" generally mean including the features explicitly stated, but not excluding other elements.
[0149] In this application, the term "about" generally refers to a variation within a range of 0.5%-10% above or below a specified value, for example, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below a specified value. DETAILED DESCRIPTION OF THE INVENTION
[0151] In one aspect, the present application provides a pharmaceutical combination comprising:
[0152] a) a preventive and / or therapeutically effective amount of ascorbic acid or a derivative thereof; and
[0153] b) a preventively and / or therapeutically effective amount of a second therapeutic agent selected from the group consisting of a Notch signaling pathway inhibitor, an Hh signaling pathway inhibitor, a Porcupine inhibitor, a RXRα inhibitor, Niclosamide, a CK1a inhibitor and a Frizzled receptor inhibitor.
[0154] On the other hand, the present application also provides the use of a combination of ascorbic acid or its derivatives and a second therapeutic agent in the preparation of a medicament for preventing and / or treating tumors, wherein the second therapeutic agent is selected from: Notch signaling pathway inhibitors, HH signaling pathway inhibitors, RXRα inhibitors and Wnt signaling pathway inhibitors.
[0155] For example, the second therapeutic agent may include a Notch signaling pathway inhibitor.
[0156] For example, the second therapeutic agent may include an inhibitor of the SHH signaling pathway.
[0157] For example, the second therapeutic agent may include a RXRα inhibitor.
[0158] For example, the second therapeutic agent may include a Wnt signaling pathway inhibitor.
[0159] On the other hand, the present application also provides a method for preventing and / or treating tumors, comprising administering to a subject in need thereof:
[0160] a) ascorbic acid or its derivatives; and
[0161] b) a second therapeutic agent, wherein the second therapeutic agent is selected from: a Notch signaling pathway inhibitor, an HH signaling pathway inhibitor, a RXRα inhibitor and a Wnt signaling pathway inhibitor.
[0162] On the other hand, the present application also provides a method for monitoring a subject's response to a drug, the method comprising:
[0163] a) administering ascorbic acid or a derivative thereof and a second therapeutic agent to the subject, wherein the second therapeutic agent is selected from the group consisting of: a Notch signaling pathway inhibitor, an HH signaling pathway inhibitor, a RXRα inhibitor, and a Wnt signaling pathway inhibitor; and
[0164] b) detecting one or more of the following changes in the subject after the administration of a): blood alkaline phosphatase level and / or activity, lactate dehydrogenase level and / or activity, CADM1 gene expression level, CD44 gene expression level, livin gene expression level, HIF-1α gene expression level, ET-1 gene expression level, IGF-1R gene expression level, STAT3 gene expression level, CEA gene expression level, CA199 gene expression level, CA125 gene expression level, AFP gene expression level, CA724 gene expression level, β-HCG gene expression level.
[0165] On the other hand, the present application also provides a kit, which includes the drug combination described in the present application.
[0166] Drug combinations
[0167] The drug combination of the present application comprises: a) a preventive and / or therapeutically effective amount of ascorbic acid or its derivatives described in the present application; and b) a preventive and / or therapeutically effective amount of a second therapeutic agent described in the present application selected from the following group: Notch signaling pathway inhibitors, HH signaling pathway inhibitors, Porcupine inhibitors, RXRα inhibitors, Niclosamide, CK1a inhibitors and Frizzled receptor inhibitors. Among them, the ascorbic acid or its derivatives may include ascorbic acid, ascorbic acid derivatives and any combination thereof. The second therapeutic agent may include any one of Notch signaling pathway inhibitors, HH signaling pathway inhibitors, Porcupine inhibitors, RXRα inhibitors, Niclosamide, CK1a inhibitors, and Frizzled receptor inhibitors, or any combination thereof.
[0168] For example, the second therapeutic agent may include a Notch signaling pathway inhibitor.
[0169] For example, the second therapeutic agent may include an HH signaling pathway inhibitor.
[0170] For example, the second therapeutic agent may include a Porcupine inhibitor.
[0171] For example, the second therapeutic agent may include a RXRα inhibitor.
[0172] For example, the second therapeutic agent may include Niclosamide.
[0173] For example, the second therapeutic agent may include a CK1a inhibitor.
[0174] For example, the second therapeutic agent may include a Frizzled receptor inhibitor.
[0175] For example, the ratio of the effective amount of the second therapeutic agent to the effective amount of ascorbic acid or a derivative thereof is from about 1:1 to about 1:5000.
[0176] For example, the ratio of the effective amount of the second therapeutic agent to the effective amount of ascorbic acid or a derivative thereof is from about 1:10 to about 1:5000.
[0177] For example, the effective amount of the second therapeutic agent to the effective amount of the ascorbic acid or its derivative is in a ratio of 1:1 to about 1:20, about 1:5 to about 1:20, about 1:10 to about 1:20, about 1:10 to about 1:25, about 1:10 to about 1:50, about 1:10 to about 1:100, about 1:10 to about 1:150, about 1:10 to about 1:200, about 1:10 to about 1:250, about 1:10 to about 1:300, about 1:10 From about 1:400 to about 1:450, from about 1:10 to about 1:500, from about 1:10 to about 1:550, from about 1:10 to about 1:600, from about 1:10 to about 1:650, from about 1:10 to about 1:700, from about 1:10 to about 1:800, from about 1:10 to about 1:900, from about 1:10 to about 1:1000, from about 1:10 to about 1:1500, from about 1:10 to about 1:2000, from about 1:10 to about 1:3000, from about 1:10 to about 1:3500, from about 1:10 to about 1:4000 000, about 1:10 to about 1:4000, about 1:10 to about 1:5000, about 1:5 to about 1:20, about 1:5 to about 1:25, about 1:5 to about 1:35, about 1:5 to about 1:50, about 1:5 to about 1:100, about 1:5 to about 1:150, about 1:5 to about 1:200, about 1:25 to about 1:50, about 1:25 to about 1:100, about 1:25 to about 1:150, about 1:25 to about 1:200, about 1:25 to about 1:1000, about 1:25 to about 1:5000, about 1:50 to about 1:100, about 1:50 to about 1:150, about 1:50 to about 1:200, about 1:50 to about 1:300, about 1:50 to about 1:500, about 1:50 to about 1:1000, about 1:50 to about 1:2000, about 1:50 to about 1:4000 or about 1:50 to about 1:5000, about 1:4500 to about 1:5500.
[0178] For example, the ratio of the effective amount of the second therapeutic agent to the effective amount of the ascorbic acid or its derivative is about 1:1, 1:5, 1:7, 1:10, 1:12, 1:15, 1:17, 1:20, 1:25, 1:35, 1:40, 1:45, 1:50, 1:55, 1:60, 1:65, 1:70, 1:75, 1:80, 1:85, 1:90, 1:100. , 1:120, 1:150, 1:180, 1:200, 1:220, 1:250, 1:280, 1:300, 1:320, 1:350, 1:380, 1:400, 1:420, 1:450, 1:480, 1:500, 1:550, 1:600, 1:650, 1:700, 1:750, 1:800, 1:850, 1:900, 1:120 : 950, 1: 1000, 1: 1100, 1: 1200, 1: 1300, 1: 1400, 1: 1500, 1: 1600, 1: 1700, 1: 1800, 1: 1900, 1: 2000, 1: 2100, 1: 2200, 1: 2300, 1: 2400, 1: 2500, 1: 2600, 1: 2700, 1: 2800, 1: 2900, 1 1:4400, 1:4500, 1:4600, 1:4700, 1:4800, 1:4900 or 1:5000.
[0179] For example, the effective amount ratio may include an effective amount molar ratio and / or an effective amount mass ratio.
[0180] For example, the mass ratio of the second therapeutic agent to the ascorbic acid or its derivative is about 5000:1 to about 1:5000.
[0181] For example, the mass ratio of the second therapeutic agent to the ascorbic acid or its derivative is about 20:1 to 1:1, about 20:1 to about 5:1, about 20:1 to about 10:1, about 25:1 to about 10:1, about 50:1 to about 10:1, about 100:1 to about 10:1, about 150:1 to about 10:1, about 200:1 to about 10:1, about 250:1 to about 10:1, about 300:1 to about 10:1, about 400:1 to about 10:1, about 450:1 to about 10:1, about 10:1 to about 500:1, about 10:1 to about 550:1, about 10:1 to about 600:1, about 10:1 to about 650:1, about 700:1 to about 10:1, about 800:1 to about 10:1, 1 to about 10:1, about 1000:1 to about 10:1, about 1500:1 to about 10:1, about 2000:1 to about 10:1, about 3000:1 to about 10:1, about 4000:1 to about 10:1, about 5000:1 to about 10:1, about 20:1 to about 5:1, about 1000:1 to about 50:1, about 2000:1 to about 50:1, about 3000:1 to about 50:1, about 4000:1 to about 50:1, about 5000:1 to about 1:50, about 20:1 to 1:20, about 20:1 to about 1:20, about 20:1 to about 1:25, about 25:1 to about 50:1, about 50:1 to about 1:100, about 100:1 to about 1 1 to about 1:100, about 150:1 to about 1:100, about 200:1 to about 1:200, about 250:1 to about 1:500, about 300:1 to about 1:1000, about 400:1 to about 1:100, about 450:1 to about 1:500, about 10:1 to about 1:500, about 10:1 to about 1:550, about 10:1 to about 1:600, about 10:1 to about 1:650, about 700:1 to about 1:650, about 800:1 to about 1:800, about 900:1 to about 1:900, about 1000:1 to about 1:1000, about 1500:1 to about 1:1000, about 2000:1 to about 1:1500, about 3000:1 to about 1:500, about 4 1:200, about 1:10 to about 1:200, about 1:10 to about 1:250, about 1:10 to about 1:500, about 1:10 to about 1:100, about 1:10 to about 1:150, about 1:10 to about 1:200, about 1:10 to about 1:250, about 1:10 to about 1:500, about 1:10 to about 1:100, about 1:10 to about 1:150, about 1:10 to about 1:200, about 1:10 to about 1:250, about 1:10 to about 1:300, about 1:10 to about 1:400, about 1:10 to about 1:450, about 1:10 to about 1:500, about 1:10 to about 1:550,From about 1:10 to about 1:600, from about 1:10 to about 1:650, from about 1:10 to about 1:700, from about 1:10 to about 1:800, from about 1:10 to about 1:900, from about 1:10 to about 1:1000, from about 1:10 to about 1:1500, from about 1:10 to about 1:2000, from about 1:10 to about 1:3000, from about 1:10 to about 1:4000, from about 1:10 to about 1:5000, from about 1:5 to about 1:20, from about 1:5 to about 1:25, from about 1:5 to about 1:35, from about 1:5 to about 1:50, from about 1:5 to about 1:100, from about 1:5 to about 1:150, from about 1:5 From about 1:200, from about 1:25 to about 1:50, from about 1:25 to about 1:100, from about 1:25 to about 1:150, from about 1:25 to about 1:200, from about 1:25 to about 1:1000, from about 1:25 to about 1:5000, from about 1:50 to about 1:100, from about 1:50 to about 1:150, from about 1:50 to about 1:200, from about 1:50 to about 1:300, from about 1:50 to about 1:500, from about 1:50 to about 1:1000, from about 1:50 to about 1:2000, from about 1:50 to about 1:3000, from about 1:50 to about 1:4000, or from about 1:50 to about 1:5000.
[0182] For example, the mass ratio of the second therapeutic agent to the ascorbic acid or its derivative is about 1:10 to about 1:5000.
[0183] For example, the second therapeutic agent and the ascorbic acid or its derivatives can each be from different sources, such as prepared, produced or sold by different merchants. For example, the ascorbic acid or its derivatives prepared, produced or sold do not have to be a single component or pure, as long as it contains a compound capable of releasing ascorbic acid (vitamin C) in vivo or in vitro, or its solvate, hydrate, salt, and / or an analog containing ascorbic acid (for example, wherein one or more hydroxyl groups of ascorbic acid are replaced by another structural part, and wherein the ascorbic acid analog substantially maintains the stable activity of ascorbic acid in vitro or in vivo) are within the scope of the present application. Similarly, the second therapeutic agent prepared, produced or sold does not have to be a single component or pure, as long as it contains any one or more of the second therapeutic agents described in the present application that can be released in vivo or in vitro, or its solvate, hydrate, salt, and / or an analog containing any one or more of the second therapeutic agents (for example, it contains group modification or substitution, and the analog substantially maintains the stable activity of any second therapeutic agent in vitro or in vivo) are within the scope of the present application.
[0184] For example, the second therapeutic agent and the ascorbic acid or a derivative thereof are each present in different containers.
[0185] For example, the second therapeutic agent and the ascorbic acid or its derivative are respectively present in different containers, and the amount of the second therapeutic agent and the amount of the ascorbic acid or its derivative can be set according to their effective amount ratio or not.
[0186] For example, the second therapeutic agent can be present in 1 or more containers, such as 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more.
[0187] For example, the ascorbic acid or a derivative thereof may be present in 1 or more containers, such as 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more.
[0188] For example, the container may include a medicine box, a medicine box, a medicine bottle, a medicine bag, a blister, a tube, a syringe, etc.; for example, the medicine bottle may include a sealed glass ampoule, a test tube, a vial, a flask, a bottle, etc.; for example, the container may be composed of an organic polymer such as glass, polycarbonate, polystyrene, or a packaging material lined with foil such as ceramic, metal, composite film, cellophane, aluminum or alloy, etc., and any other appropriate material that can generally be used to hold reagents.
[0189] For example, the second therapeutic agent and the ascorbic acid or its derivative may be present in separate containers, and may be formulated into a preparation with a suitable carrier simultaneously or separately when necessary.
[0190] For example, the second therapeutic agent is mixed with the ascorbic acid or its derivative to form a suitable formulation.
[0191] For example, the second therapeutic agent and the ascorbic acid or its derivative are each formulated into different suitable formulations.
[0192] For example, the second therapeutic agent and the ascorbic acid or its derivative may be present in separate containers in the form of formulations.
[0193] For example, the pharmaceutical combination comprises a first formulation and a second formulation, wherein the first formulation comprises the ascorbic acid or a derivative thereof and a first pharmaceutically acceptable carrier, and the second formulation comprises the second therapeutic agent and a second pharmaceutically acceptable carrier.
[0194] For example, the first preparation and the second preparation may be in the same dosage form or in different dosage forms.
[0195] For example, the first preparation and the second preparation can be any one of the dosage forms such as pills, powders, tablets, granules, gels, hard capsules, soft capsules, syrups, mixtures, dews, injections, aerosols, ointments, films, suppositories, and pills, or any different combinations thereof.
[0196] For example, the first preparation and the second preparation may be present in the form of preparations suitable for the same administration method.
[0197] For example, the first preparation and the second preparation may be in the form of preparations suitable for different administration modes.
[0198] For example, the pharmaceutical combination comprises a pharmaceutical composition, and the pharmaceutical composition comprises the second therapeutic agent and the ascorbic acid or a derivative thereof.
[0199] For example, the content of the second therapeutic agent in the pharmaceutical composition is about 1% to about 50% (w / w).
[0200] About 5% (w / w) to about 50% (w / w), about 10% (w / w) to about 40% (w / w), about 20% (w / w) to about 50% (w / w), about 10% (w / w) to about 30% (w / w), about 20% (w / w) to about 40% (w / w), about 1% (w / w) to about 5% (w / w). About 30% (w / w) to about 50% (w / w), about 5% to about 20% (w / w), about 20% (w / w) to about 30% (w / w).
[0201] For example, the content of the second therapeutic agent in the pharmaceutical composition is about 5% to about 20% (w / w).
[0202] For example, the second therapeutic agent is present in an amount of about 5% (w / w) to about 10% (w / w), about 10% (w / w) to about 20% (w / w), about 10% (w / w) to about 15% (w / w), about 10% (w / w) to about 18% (w / w), about 5% (w / w) to about 15% (w / w).
[0203] For example, the content of the ascorbic acid or its derivative in the pharmaceutical composition is about 50% to about 95% (w / w).
[0204] For example, the content of the ascorbic acid or its derivatives is about 50% (w / w) to about 60% (w / w), about 50% (w / w) to about 70% (w / w), about 60% (w / w) to about 80% (w / w), about 50% (w / w) to about 90% (w / w), about 60% (w / w) to about 90% (w / w), about 55% (w / w) to about 75% (w / w). About 70% (w / w) to about 90% (w / w), about 80 to about 95% (w / w).
[0205] For example, the content of the ascorbic acid or its derivative in the pharmaceutical composition is about 80% to about 95% (w / w).
[0206] For example, the second therapeutic agent is present in an amount of about 80% to about 85% (w / w), about 80% to about 90% (w / w), about 85% to about 95% (w / w), about 85% to about 90% (w / w).
[0207] Uses and methods
[0208] The present application also provides the use of a combination of ascorbic acid or its derivatives and a second therapeutic agent in the preparation of a medicament for preventing and / or treating tumors, wherein the second therapeutic agent is selected from: a Notch signaling pathway inhibitor, an HH signaling pathway inhibitor, an RXRα inhibitor and a Wnt signaling pathway inhibitor.
[0209] The present invention also provides a method for preventing and / or treating tumors, comprising administering to a subject in need thereof:
[0210] a) ascorbic acid or a derivative thereof; and b) a second therapeutic agent, wherein the second therapeutic agent is selected from the group consisting of: a Notch signaling pathway inhibitor, an HH signaling pathway inhibitor, a RXRα inhibitor, and a Wnt signaling pathway inhibitor.
[0211] The present application also provides a method for monitoring a subject's response to a drug, the method comprising:
[0212] a) administering ascorbic acid or a derivative thereof and a second therapeutic agent to the subject, wherein the second therapeutic agent is selected from the group consisting of: a Notch signaling pathway inhibitor, an HH signaling pathway inhibitor, a RXRα inhibitor, and a Wnt signaling pathway inhibitor; and
[0213] b) detecting one or more of the following changes in the subject after the administration of a): blood alkaline phosphatase level and / or activity, lactate dehydrogenase level and / or activity, CADM1 gene expression level, CD44 gene expression level, livin gene expression level, HIF-1α gene expression level, ET-1 gene expression level, IGF-1R gene expression level, STAT3 gene expression level, CEA gene expression level, CA199 gene expression level, CA125 gene expression level, AFP gene expression level, CA724 gene expression level, β-HCG gene expression level.
[0214] For example, the expression level of the gene may include modification and / or mutation of genomic DNA, expression level of mRNA, expression level of protein,
[0215] For example, the detection can be selected from PCR, real-time quantitative PCR, digital PCR, liquid chip, solid-state chip, in situ hybridization, conventional sequencing and high-throughput sequencing to detect modification and / or mutation of genomic DNA and expression level of mRNA.
[0216] For example, the detection can be selected from liquid chip, solid state chip, enzyme-linked immunosorbent assay, radioimmunoassay, chemiluminescent immunoassay, mass spectrometry, high performance liquid chromatography, Western labeling and sequencing to detect the expression level of the protein.
[0217] For example, the ascorbic acid or its derivatives may include ascorbic acid, ascorbic acid derivatives and any combination thereof. The second therapeutic agent may include any one of Notch signaling pathway inhibitors, HH signaling pathway inhibitors, Wnt signaling pathway inhibitors and RXRα inhibitors, or any combination thereof.
[0218] For example, the second therapeutic agent may include a Notch signaling pathway inhibitor.
[0219] For example, the second therapeutic agent may include an HH signaling pathway inhibitor.
[0220] For example, the second therapeutic agent may include a RXRα inhibitor.
[0221] For example, the second therapeutic agent may include an HH signaling pathway inhibitor.
[0222] For example, the tumor includes solid tumors and non-solid tumors.
[0223] For example, the solid tumor can be selected from the following group: liver cancer, stomach cancer, lung cancer, breast cancer, colon cancer, rectal cancer, renal cell carcinoma, hepatocellular carcinoma, non-small cell lung cancer, small intestine cancer, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, testicular cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, non-Hodgkin's lymphoma, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, solid tumors in children, bladder cancer, kidney or ureter cancer, renal pelvis cancer, central nervous system (CNS) tumors, primary CNS lymphoma, tumor angiogenesis, spinal vertebral tumors, brain stem gliomas, pituitary adenomas, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, and metastatic lesions of the above cancers.
[0224] For example, the non-solid tumor can be selected from the following group: chronic lymphocytic leukemia (CLL), acute leukemia, acute lymphoid leukemia (ALL), B-cell acute lymphoid leukemia (B-ALL), T-cell acute lymphoid leukemia (T-ALL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), B-cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell or large cell follicular lymphoma, malignant lymphoproliferative diseases, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm and Waldenstrom macroglobulinemia.
[0225] For example, the solid tumor includes osteosarcoma and / or colon cancer.
[0226] For example, the non-solid tumor includes lymphoma.
[0227] For example, the second therapeutic agent and the ascorbic acid or a derivative thereof are configured to be administered to the subject simultaneously.
[0228] For example, Niclosamide combined with the ascorbic acid or its derivatives can be used to prevent and / or treat tumors. For example, Niclosamide combined with the ascorbic acid or its derivatives can be used to prevent and / or treat lymphoma, osteosarcoma and / or colon cancer. For example, Dvl-2 inhibitors combined with the ascorbic acid or its derivatives can be used to prevent and / or treat lymphoma, osteosarcoma and / or colon cancer. For example, Wnt signaling pathway inhibitors combined with the ascorbic acid or its derivatives can be used to prevent and / or treat lymphoma, osteosarcoma and / or colon cancer.
[0229] For example, the simultaneous administration to the subject may include the second therapeutic agent and the ascorbic acid or its derivative being administered to the subject at a time interval of no more than 1 hour. For example, the time interval is 60 minutes, 55 minutes, 50 minutes, 45 minutes, 40 minutes, 35 minutes, 30 minutes, 25 minutes, 20 minutes, 15 minutes, 10 minutes, 8 minutes, 5 minutes, 3 minutes, 2 minutes, 1 minute, or administered together in a mixed form.
[0230] For example, the second therapeutic agent and the ascorbic acid or a derivative thereof are formulated to be administered separately to the subject.
[0231] For example, the separate administration to the subject can include a time interval of greater than 1 hour between the administration of the second therapeutic agent and the administration of the ascorbic acid or its derivative to the subject. For example, the time interval is 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 5.5 hours, 6 hours, 6.5 hours, 7 hours, 7.5 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 15 hours, 18 hours, 21 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, or longer.
[0232] For example, the administration may include oral administration, intravenous administration, intramuscular administration, in situ administration at the tumor site, inhalation, rectal administration, vaginal administration, transdermal administration, or administration via a subcutaneous reservoir, or any combination thereof.
[0233] For example, the separate administration to the subject may include alternating administration of the second therapeutic agent and the ascorbic acid or its derivative, such as administering the second therapeutic agent followed by administering the ascorbic acid or its derivative, or administering the ascorbic acid or its derivative followed by administering the second therapeutic agent.
[0234] For example, the administering of the second therapeutic agent can include administering once.
[0235] For example, the administering of the second therapeutic agent can include consecutive administrations 2 or more times, e.g., 3 or more times, 4 or more times, 5 or more times, 6 or more times, 7 or more times, 8 or more times, 9 or more times, 10 or more times.
[0236] For example, the administering of the ascorbic acid or a derivative thereof may include administering once.
[0237] For example, the administering of the ascorbic acid or a derivative thereof may comprise consecutive administrations 2 or more times, e.g., 3 or more times, 4 or more times, 5 or more times, 6 or more times, 7 or more times, 8 or more times, 9 or more times, 10 or more times.
[0238] For example, the medicament is formulated such that the second therapeutic agent is administered at a dose of about 1 mg / kg to about 100 mg / kg.
[0239] For example, the second therapeutic agent is administered at a dose of about 10 mg / kg to about 100 mg / kg, 10 mg / kg to about 80 mg / kg, 10 mg / kg to about 50 mg / kg, 20 mg / kg to about 100 mg / kg, 30 mg / kg to about 80 mg / kg, 1 mg / kg to about 30 mg / kg, 1 mg / kg to about 20 mg / kg, about 1 mg / kg to about 5 mg / kg, 5 mg / kg to about 10 mg / kg, 3 mg / kg to about 8 mg / kg, 5 mg / kg to about 30 mg / kg, 30 mg / kg to about 70 mg / kg, 40 mg / kg to about 60 mg / kg, 20 mg / kg to about 50 mg / kg, 30 mg / kg to about 60 mg / kg, 20 mg / kg to about 70 mg / kg.
[0240] For example, the subject of administration is a mouse. For example, the medicament is configured so that the second therapeutic agent is administered at a dose of about 10 mg / kg to about 100 mg / kg.
[0241] For example, the subject of administration is a human. For example, the medicament is configured such that the second therapeutic agent is administered at a dose of about 1 mg / kg to about 10 mg / kg.
[0242] For example, the medicament is formulated such that the ascorbic acid or a derivative thereof is administered at a dose of about 0.05 g / kg to about 2.5 g / kg.
[0243] For example, the ascorbic acid or its derivatives are present in an amount of about 0.05 g / kg to about 0.1 g / kg, about 0.1 g / kg to about 0.2 g / kg, about 0.15 g / kg to about 0.25 g / kg, about 0.05 g / kg to about 0.15 g / kg, about 0.05 g / kg to about 2.5 g / kg, about 0.25 g / kg to about 1 g / kg, about 0.35 g / kg to about 0.5 g / kg, about 0.5 g / kg to about Doses of about 1 g / kg to about 1 g / kg, about 0.5 g / kg to about 2.5 g / kg, about 0.5 g / kg to about 2 g / kg, about 1 g / kg to about 2 g / kg, about 1 g / kg to about 2.5 g / kg, about 1.5 g / kg to about 2.5 g / kg, about 0.1 g / kg to about 2.5 g / kg, about 0.5 g / kg to about 2 g / kg, and about 0.05 g / kg to about 0.2 g / kg are administered.
[0244] For example, the subject of administration is a mouse. For example, the drug is formulated so that the ascorbic acid or a derivative thereof is administered at a dose of about 0.5 g / kg to about 2.5 g / kg.
[0245] For example, the subject of administration is a human. For example, the medicament is formulated so that the ascorbic acid or a derivative thereof is administered at a dose of about 0.05 g / kg to about 0.25 g / kg.
[0246] For example, the medicament is formulated such that the second therapeutic agent and the ascorbic acid or a derivative thereof are administered in a mass ratio of about 1:5 to about 1:5000.
[0247] For example, the medicament is formulated such that the second therapeutic agent and the ascorbic acid or its derivative are in a ratio of about 1:1 to about 1:20, about 1:5 to about 1:20, about 1:10 to about 1:20, about 1:10 to about 1:25, about 1:10 to about 1:50, about 1:10 to about 1:100, about 1:10 to about 1:150, about 1:10 to about 1:200, about 1:10 to about 1:250, about 1:10 to about 1:300, about 1:10 to about 1:300. 400, about 1:10 to about 1:450, about 1:10 to about 1:500, about 1:10 to about 1:550, about 1:10 to about 1:600, about 1:10 to about 1:650, about 1:10 to about 1:700, about 1:10 to about 1:800, about 1:10 to about 1:900, about 1:10 to about 1:1000, about 1:10 to about 1:1500, about 1:10 to about 1:2000, about 1:10 to about 1:3000, about 1:10 to about 1:4000 1:10 to about 1:4000, about 1:10 to about 1:5000, about 1:5 to about 1:20, about 1:5 to about 1:25, about 1:5 to about 1:35, about 1:5 to about 1:50, about 1:5 to about 1:100, about 1:5 to about 1:150, about 1:5 to about 1:200, about 1:25 to about 1:50, about 1:25 to about 1:100, about 1:25 to about 1:150, about 1:25 to about 1:200, about 1:25 to about A mass ratio of 1:1000, about 1:25 to about 1:5000, about 1:50 to about 1:100, about 1:50 to about 1:150, about 1:50 to about 1:200, about 1:50 to about 1:300, about 1:50 to about 1:500, about 1:50 to about 1:1000, about 1:50 to about 1:2000, about 1:50 to about 1:4000 or about 1:50 to about 1:5000, about 1:4500 to about 1:5000 is applied.
[0248] For example, the medicament is formulated such that the second therapeutic agent and the ascorbic acid or a derivative thereof are administered in a mass ratio of about 1:5 to about 1:100.
[0249] For example, the medicament is formulated so that the second therapeutic agent and the ascorbic acid or a derivative thereof are administered in a mass ratio of about 1:5 to about 1:20, about 1:10 to about 1:20, about 1:10 to about 1:25, about 1:10 to about 1:50, about 1:10 to about 1:100, about 1:5 to about 1:25, about 1:5 to about 1:35, about 1:5 to about 1:50, about 1:30 to about 1:80, about 1:40 to about 1:80, about 1:20 to about 1:100, about 1:20 to about 1:60, about 1:20 to about 1:50, about 1:5 to about 1:100, about 1:25 to about 1:50, about 1:25 to about 1:100, about 1:50 to about 1:100, about 1:25 to about 1:50, about 1:25 to about 1:100, and about 1:50 to about 1:100.
[0250] For example, the medicament is formulated such that the second therapeutic agent and the ascorbic acid or its derivative are administered in an effective amount ratio of about 1:5 to about 1:5000.
[0251] For example, the medicament is formulated such that the second therapeutic agent and the ascorbic acid or its derivative are in a ratio of about 1:1 to about 1:20, about 1:5 to about 1:20, about 1:10 to about 1:20, about 1:10 to about 1:25, about 1:10 to about 1:50, about 1:10 to about 1:100, about 1:10 to about 1:150, about 1:10 to about 1:200, about 1:10 to about 1:250, about 1:10 to about 1:300, about 1:10 to about 1:300. 400, about 1:10 to about 1:450, about 1:10 to about 1:500, about 1:10 to about 1:550, about 1:10 to about 1:600, about 1:10 to about 1:650, about 1:10 to about 1:700, about 1:10 to about 1:800, about 1:10 to about 1:900, about 1:10 to about 1:1000, about 1:10 to about 1:1500, about 1:10 to about 1:2000, about 1:10 to about 1:3000, about 1:10 to about 1:450, about 1:10 to about 1:5 :10 to about 1:4000, about 1:10 to about 1:5000, about 1:5 to about 1:20, about 1:5 to about 1:25, about 1:5 to about 1:35, about 1:5 to about 1:50, about 1:5 to about 1:100, about 1:5 to about 1:150, about 1:5 to about 1:200, about 1:25 to about 1:50, about 1:25 to about 1:100, about 1:25 to about 1:150, about 1:25 to about 1:200, about 1:25 to about 1:50 An effective amount ratio of about 1:1000, about 1:25 to about 1:5000, about 1:50 to about 1:100, about 1:50 to about 1:150, about 1:50 to about 1:200, about 1:50 to about 1:300, about 1:50 to about 1:500, about 1:50 to about 1:1000, about 1:50 to about 1:2000, about 1:50 to about 1:4000, or about 1:50 to about 1:5000, about 1:4500 to about 1:5000 is administered.
[0252] For example, the medicament is formulated such that the second therapeutic agent and the ascorbic acid or a derivative thereof are administered in an effective amount ratio of about 1:5 to about 1:100.
[0253] For example, the medicament is formulated so that the second therapeutic agent and the ascorbic acid or a derivative thereof are administered in an effective amount ratio of about 1:5 to about 1:20, about 1:10 to about 1:20, about 1:10 to about 1:25, about 1:10 to about 1:50, about 1:10 to about 1:100, about 1:5 to about 1:25, about 1:5 to about 1:35, about 1:5 to about 1:50, about 1:30 to about 1:80, about 1:40 to about 1:80, about 1:20 to about 1:100, about 1:20 to about 1:60, about 1:20 to about 1:50, about 1:5 to about 1:100, about 1:25 to about 1:50, about 1:25 to about 1:100, about 1:50 to about 1:100, about 1:25 to about 1:50, about 1:25 to about 1:100, about 1:50 to about 1:100.
[0254] Inhibitors
[0255] In the present application, the Notch signaling pathway inhibitor, HH signaling pathway inhibitor, RXRα inhibitor, and Wnt signaling pathway inhibitor may comprise small molecule compounds.
[0256] For example, the Notch signaling pathway inhibitor can include CB-103, FLI-06, JI051, PsoralidinTangeretin, Carvacrol, Notch inhibitor 1, BMS-906024, IMR-1, IMR-1A, Z-Ile-Leu-aldehyde, ZLDI-8, Semagacestat, BruceineD, RO4929097, LY-411575, YO-01027, Crenigacestat, Avagacestat, Z-Ile-Leu-aldehyde, MK0752 and / or PF-03084014.
[0257] For example, the Notch signaling pathway inhibitor may include a gamma secretase inhibitor, an ADAM-17 inhibitor, a Notch ligand inhibitor, a Notch receptor inhibitor and / or a CSL-DNA binding protein inhibitor.
[0258] For example, the Notch signaling pathway inhibitor may include a Notch ligand inhibitor.
[0259] For example, the Notch ligand inhibitor may include a Delta-like 1 inhibitor, a Delta-like 3 inhibitor, a Delta-like 4 inhibitor, a Jagged 1 inhibitor and / or a Jagged 2 inhibitor.
[0260] For example, the Jagged 1 inhibitor may include Carvacrol.
[0261] For example, the Notch signaling pathway inhibitor may include a Notch receptor inhibitor.
[0262] For example, the Notch receptor inhibitor may include a Notch1 receptor inhibitor, a Notch2 receptor inhibitor, a Notch3 receptor inhibitor and / or a Notch4 receptor inhibitor.
[0263] For example, the Notch receptor inhibitor may include Tangeretin, Carvacrol, Notch inhibitor 1, BMS-906024, IMR-1, IMR-1A, Z-Ile-Leu-aldehyde, Semagacestat and / or Bruceine D.
[0264] For example, the Notch1 receptor inhibitor may include Tangeretin, Carvacrol and / or Notch inhibitor 1.
[0265] For example, the Notch3 receptor inhibitor may include Notch inhibitor 1.
[0266] For example, the ADAM-17 inhibitor may include ZLDI-8.
[0267] For example, the Notch signaling pathway inhibitor comprises a γ-secretase inhibitor.
[0268] For example, the gamma secretase inhibitor may include RO4929097, LY-411575, YO-01027, Crenigacestat, Semagacestat, Avagacestat, Z-Ile-Leu-aldehyde, MK0752 and / or PF-03084014.
[0269] For example, the γ-secretase inhibitor comprises MK0752, RO4929097 and / or PF-03084014.
[0270] For example, the HH signaling pathway inhibitor may include Jervine, Ciliobrevin D, RU-SKI43 hydrochloride, RU-SKI43, JK184, Cyclopamine, Mebendazole, Ciliobrevin A, SANT-1, Vismodegib, GANT 61, HhAntag, Saridegib, MRT-83, PF-5274857, 20(S)-Hydroxycholesterol, CUR61414, MK-4101, Vismodegib, Sonidegib and / or Glasdegib.
[0271] For example, the HH signaling pathway inhibitor may include a Hedgehog inhibitor, a Gli inhibitor and / or a Smo inhibitor.
[0272] For example, the HH signaling pathway inhibitor may include a Hedgehog inhibitor.
[0273] For example, the Hedgehog inhibitor may include Jervine, Ciliobrevin D, RU-SKI 43 hydrochloride, RU-SKI 43, JK184, Cyclopamine, Mebendazole, Ciliobrevin A, SANT-1, Vismodegib, CUR61414, MK-4101 and / or Dynarrestin.
[0274] For example, the HH signaling pathway inhibitor may include a Gli inhibitor.
[0275] For example, the Gli inhibitor may include GANT 61 and / or HhAntag.
[0276] For example, the Smo inhibitor may include Saridegib, MRT-83, Jervine, SANT-1, PF-5274857, 20(S)-Hydroxycholesterol, CUR61414, MK-4101, Vismodegib, Sonidegib and / or Glasdegib.
[0277] For example, the HH signaling pathway inhibitor comprises a SMO inhibitor.
[0278] For example, the SMO inhibitor may comprise Vismodegib, Sonidegib and / or Glasdegib.
[0279] For example, the Wnt signaling pathway inhibitor may include a Tankyrases inhibitor, a Porcupine inhibitor, a Dvl-2 inhibitor, a DKK inhibitor, a CK1a inhibitor and / or a Frizzled receptor inhibitor.
[0280] For example, the Wnt signaling pathway inhibitor may include a Porcupine inhibitor, a Dvl-2 inhibitor, a CK1a inhibitor, and / or a Frizzled receptor inhibitor.
[0281] For example, the Wnt signaling pathway inhibitor may comprise a Tankyrases inhibitor.
[0282] For example, the Tankyrases inhibitor may comprise IWR1, XAV939, NVP-TNKS656 and / or JW74.
[0283] For example, the Wnt signaling pathway inhibitor may comprise a Porcupine inhibitor.
[0284] For example, the porcupine inhibitor may comprise IWP-2, LGK974 and / or ETC-159.
[0285] For example, the porcupine inhibitor may comprise LGK974 and / or ETC-159.
[0286] For example, the Wnt signaling pathway inhibitor may comprise a DKK inhibitor.
[0287] For example, the DKK inhibitor may comprise DKN-01.
[0288] For example, the Wnt signaling pathway inhibitor may comprise a CK1a inhibitor.
[0289] For example, the CK1a inhibitor may comprise Pyrvinium.
[0290] For example, the Wnt signaling pathway inhibitor may comprise a Dvl-2 inhibitor.
[0291] For example, the Dvl-2 inhibitor may comprise NSC668036, J01-017a, Niclosamide and / or Sulindac.
[0292] For example, the Dvl-2 inhibitor may comprise Niclosamide and / or Sulindac.
[0293] For example, the Dvl-2 inhibitor may not comprise Sulindac.
[0294] For example, the Wnt signaling pathway inhibitor may comprise a Frizzled receptor inhibitor.
[0295] In certain embodiments, the RXRα inhibitor comprises berberine or a pharmaceutically acceptable salt thereof.
[0296] For example, the pharmaceutically acceptable salt may include berberine and any one or more salts formed from organic acids such as R-(+)-α-organic acid, hydroxycitric acid, eicosapentaenoic acid, docosahexaenoic acid, ursolic acid, corosolic acid, cinnamic acid, cholic acid, obeticholic acid, ursodeoxycholic acid, oleanolic acid, salicylic acid, betulinic acid, chlorogenic acid, caffeic acid, bassic acid, acetyl-L-carnitine, S-allylcysteine sulfoxide, S-methylcysteine sulfoxide, pantothenic acid, ascorbic acid, retinoic acid, niacin and biotin.
[0297] For example, the inhibitor may further comprise Fervenulin, 3-Methyltoxoflavin and / or WalrycinB.
[0298] In the present application, the Notch signaling pathway inhibitor, HH signaling pathway inhibitor, RXRα inhibitor, and Wnt signaling pathway inhibitor may also include antibodies or polypeptides. The interaction of the antibodies or polypeptides with their corresponding binding targets can reduce or hinder the activation / signal transduction of the Notch signaling pathway, the HH signaling pathway, and the Wnt signaling pathway, and / or can reduce or hinder the activity of RXRα.
[0299] For example, the antibody or polypeptide may include an antibody or binding polypeptide to gamma secretase, an antibody or binding polypeptide to ADAM-17, an antibody or binding polypeptide to Notch ligand, an antibody or binding polypeptide to Notch receptor, an antibody or binding polypeptide to CSL-DNA binding protein, an antibody or binding polypeptide to Hedgehog, an antibody or binding polypeptide to Gli, an antibody or binding polypeptide to smo, an antibody or binding polypeptide to Tankyrases, an antibody or binding polypeptide to Porcupine, an antibody or binding polypeptide to Dvl-2, an antibody or binding polypeptide to DKK, an antibody or binding polypeptide to CK1a and / or an antibody or binding polypeptide to Frizzled receptor.
[0300] For example, the Frizzled receptor antibody may include OMP18RS (Vantictumab), OMP-54F28 (Ipafricept), OMP131R10 and / or OTSA 101.
[0301] For example, the Frizzled binding polypeptide may include Fz7-21TFA, Fz7-21 and / or Foxy-5.
[0302] In the present application, the Notch signaling pathway inhibitor, HH signaling pathway inhibitor, RXRα inhibitor, and Wnt signaling pathway inhibitor may also include siRNA, shRNA, and / or CRISPR / Cas9 system. The siRNA, shRNA, and CRISPR / Cas9 system can target the coding genomic DNA or mRNA of the molecules included in the HH signaling pathway, RXRα inhibitor, and Wnt signaling pathway, thereby reducing the expression level / activity of the corresponding molecules.
[0303] For example, the siRNA, shRNA and / or CRISPR / Cas9 system can include siRNA, shRNA and / or CRISPR / Cas9 system targeting γ-secretase, ADAM-17, Notch ligand, Notch receptor, CSL-DNA binding protein, Hedgehog, Gli, Smo, Tankyrases, Porcupine, Dvl-2, DKK, CK1a and / or Frizzled receptor.
[0304] For example, the CRISPR / Cas9 system includes guide RNA and / Cas9 protein.
[0305] Ascorbic acid and its derivatives
[0306] In the present application, the ascorbic acid and its derivatives include members selected from ascorbic acid (vitamin C), ascorbic acid derivatives and combinations thereof.
[0307] For example, the ascorbic acid derivative may further include dehydroascorbic acid, ascorbic acid salts or salts of ascorbic acid derivatives.
[0308] Ascorbic acid is sensitive to the influence of environmental parameters (e.g., light, heat, oxygen) due to its α-keto lactone structure. It may be unstable in water or other aqueous solutions. Ascorbic acid derivatives with higher stability than the parent compound are prepared by means of chemically stabilizing the ascorbic acid molecule (e.g., see U.S. Patents US 5,137,723 and US 5,078,989), the contents of which are incorporated herein by reference.
[0309] For example, the ascorbic acid derivative can be an ascorbic acid analog. Typical ascorbic acid derivatives include following compounds: at least one of the hydroxyl groups of the ascorbic acid molecule (e.g., 2-OH, 3-OH, 5-OH, 6-OH) is derived by a modified group (e.g., referring to U.S. Pat. No. 5,078,989 of Ando et al.). For example, one or more of the hydroxyl groups can be substituted by another structural part. For example, the ascorbic acid and its derivatives include ascorbic acid and at least one ascorbic acid derivative.
[0310] For example, the ascorbic acid derivative may include a free 2-OH and a free 3-OH.
[0311] For example, the ascorbic acid derivatives include esters of ascorbic acid derived from at least one of 5-OH and 6-OH.
[0312] For example, the ascorbic acid derivatives include esters such as 6-O-octanoyl-ascorbic acid, 6-O-dodecanoyl-ascorbic acid, 6-O-tetradecanoyl-ascorbic acid, 6-O-octadecanoyl-ascorbic acid, 6-O-dodecandioyl-ascorbic acid, 6-O-docosanedioyl-ascorbic acid, 6-O-thapsoyl-ascorbic acid, 6-O-sebacoyl-ascorbic acid, 6-O-adipoyl-ascorbic acid.
[0313] For example, the ascorbic acid derivatives may also include esters wherein the lipophilic moiety of the molecule is a mono- or poly-unsaturated fatty acid. For example, the unsaturated fatty acid may include essential fatty acids associated with health, such as ω-3 (α-linolenic acid), ω-6 or ω-9 fatty acids. For example, esters containing amino acid residues may also be included.
[0314] For example, the ascorbic acid derivatives may also include 2-O-alkyl or 3-O-alkyl derivatives of ascorbic acid. 3-O-alkyl-ascorbic acid was reported by Nihro et al. in Chem. Pharm. Bull. 1991, 39: 1731-1735, which is incorporated herein by reference.
[0315] For example, the ascorbic acid derivative may include glycosides of ascorbic acid; such as ascorbic acid 1-glycoside, ascorbic acid 2-glycoside, ascorbic acid 3-glycoside, ascorbic acid 5-glycoside and ascorbic acid 6-glycoside.
[0316] For example, the ascorbic acid derivatives may include 2-O-(α-D-glucopyranosyl)-ascorbic acid (see, for example, U.S. Pat. No. 5,137,723) and 2-O-(β-D-glucopyranosyl)-ascorbic acid (see, for example, U.S. Patent Application No. US 2005 / 0113312). The above documents are incorporated herein by reference.
[0317] For example, the ascorbic acid derivative may include a difunctionalized derivative of ascorbic acid, such as, for example, 6-O-acyl-2-O-(α-D-glucopyranosyl)ascorbic acid (see, for example, Yamamoto et al., J. Med. Chem. 2002, 45(2): 462-468. This document is incorporated herein by reference.
[0318] For example, ascorbic acid derivatives can include phosphates of ascorbic acid. For example, ascorbic acid phosphates are alkali metal salts, alkaline earth metal salts or transition metal salts. For example, magnesium ascorbyl phosphate, sodium ascorbyl phosphate (e.g., ascorbyl-2-monophosphate sodium salt), calcium ascorbyl phosphate, potassium ascorbyl phosphate and mixed salts can be included, for example, sodium magnesium ascorbyl phosphate, sodium calcium ascorbyl phosphate, aminopropyl ascorbyl phosphate.
[0319] For example, ascorbyl phosphate can exist as a hydrate, among which dihydrate is common. A typical dihydrate can be purchased from DSM under the product name STAY-C50.
[0320] In the present application, the ascorbic acid derivative comprises a pharmaceutically acceptable ascorbate.
[0321] For example, the pharmaceutically acceptable ascorbate salts include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as calcium salt and magnesium salt, basic amino acid salts such as arginine, and organic amine salts such as triethanolamine.
[0322] For example, the salt of ascorbate or an ascorbic acid derivative may be an edible (eg, pharmaceutically acceptable) salt such as calcium, sodium, magnesium, potassium and zinc salts, and mixed salts of ascorbic acid or an ascorbic acid derivative.
[0323] For example, the pharmaceutically acceptable ascorbate comprises sodium ascorbate.
[0324] Other well-recognized ascorbic acid derivatives are also useful for the purposes of this application.
[0325] Carriers and formulations
[0326] In the present application, the dosage form of the first preparation, the second preparation or the pharmaceutical composition may include tablets, capsules, granules, powders, syrups, suspensions, suppositories, ointments, creams, gels, patches, inhalants, injections, etc. These preparations can be prepared according to conventional methods.
[0327] For example, in the case of a liquid preparation, it may be dissolved or suspended in water or other appropriate solvents when used.
[0328] For example, tablets and granules can be coated by a known method.
[0329] For example, in the case of an injection, the active ingredients (including the ascorbic acid or its derivatives described in the present application, the second therapeutic agent described in the present application) can be dissolved in water for preparation, or dissolved in physiological saline or glucose solution as needed, for example, a buffer or preservative can also be added.
[0330] For example, it can be provided in any form of preparation for oral administration or parenteral administration. For example, it can be prepared into a preparation for oral administration in the form of granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions or liquids;
[0331] For example, the preparation may be in the form of injections for intravenous administration, intramuscular administration, or subcutaneous administration, drips, percutaneous absorption preparations, transmucosal absorption preparations, nasal drops, inhalants, suppositories, or the like for parenteral administration.
[0332] For example, injections, drips and the like can be prepared in a powdered dosage form such as a freeze-dried form, and dissolved in a suitable aqueous medium such as physiological saline before use.
[0333] For example, a sustained-release preparation coated with a polymer or the like can be directly administered into an organ such as the brain.
[0334] With regard to the type of the preparation additive (carrier) used in the manufacture of the pharmaceutical preparation, the ratio of the preparation additive (carrier) to the active ingredient, or the manufacturing method of the preparation, those skilled in the art can appropriately select according to the form of the preparation. For example, as the preparation additive (carrier), inorganic or organic substances, or solid or liquid substances can be used, for example, it can be matched between 1% by weight and 90% by weight relative to the weight of the active ingredient. For example, the carrier can include lactose, glucose, mannitol, dextrin, cyclodextrin, starch, sucrose, magnesium aluminum metasilicate, synthetic aluminum silicate, sodium carboxymethyl cellulose, hydroxypropyl starch, calcium carboxymethyl cellulose, ion exchange resin, methyl cellulose, gelatin, gum arabic, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl pyrrolidone, polyvinyl alcohol, light anhydrous silicic acid, magnesium stearate, talc, tragacanth gum, bentonite, propolis, titanium oxide, sorbitan fatty acid ester, sodium lauryl sulfate, glycerin, fatty acid glyceride, purified lanolin, glyceryl gelatin, polysorbate, polyethylene glycol, vegetable oil, wax, liquid paraffin, white petrolatum, fluorocarbons, nonionic surfactants, propylene glycol, water, etc.
[0335] For example, when manufacturing a solid preparation for oral administration, the active ingredient (including the ascorbic acid or its derivative described in the present application, the second therapeutic agent described in the present application) can be mixed with a carrier component such as lactose, starch, crystalline cellulose, calcium lactate, anhydrous silicic acid, etc. to prepare a powder; for example, a binder such as sucrose, hydroxypropyl cellulose, polyvinyl pyrrolidone, a disintegrant such as carboxymethyl cellulose, carboxymethyl cellulose calcium, etc. can be further added as needed and wet or dry granulation can be performed to prepare granules; for example, when manufacturing tablets, the powder and / or granules can be directly compressed; for example, Lubricants such as magnesium stearate and talc can be added for tableting; for example, the granules or tablets can be coated with enteric solvent matrices such as hydroxypropyl methylcellulose phthalate, methacrylic acid-methyl methacrylate polymer to prepare enteric solvent preparations; for example, ethyl cellulose, carnauba wax, hydrogenated oil, etc. can be coated to prepare long-acting preparations; for example, when manufacturing capsules, powders or granules can be filled in hard capsules, and for example, the active ingredients can be directly or dissolved in glycerol, polyethylene glycol, sesame oil, olive oil, etc. and then covered with gelatin film to prepare soft capsules.
[0336] For example, when manufacturing an injection, the active ingredient can be dissolved in distilled water for injection together with a pH adjuster such as hydrochloric acid, sodium hydroxide, lactose, lactic acid, sodium, sodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, glucose, and the like, as needed; for example, it can be further aseptically filtered and filled in an ampoule; for example, mannitol, dextrin, cyclodextrin, gelatin, etc. can be further added and vacuum-freezed to prepare a dissolving injection. For example, lecithin, polysorbate 80, polyoxyethylene hydrogenated castor oil, etc. can also be added to the active ingredient and emulsified in water to prepare an emulsion for injection.
[0337] For example, when manufacturing a rectal administration agent, the active ingredient can be moistened and dissolved together with a suppository base material such as cocoa butter, triglycerides, diglycerides and monoglycerides of fatty acids, polyethylene glycol, etc., and then poured into a mold and cooled. For example, the active ingredient can also be dissolved in polyethylene glycol, soybean oil, etc. and then coated with a gelatin film.
[0338] For example, when manufacturing an external preparation for skin, the active ingredient can be added to white petrolatum, beeswax, liquid paraffin, polyethylene glycol, etc., and moistened and kneaded as needed to make an ointment; for example, it can also be kneaded with an adhesive such as rosin or an alkyl acrylate polymer and then extended on a non-woven fabric such as a polyalkyl to make a strip preparation.
[0339] For example, it can also be used as an implant or a sustained-release preparation such as a delivery system encapsulated in a microcapsule, which can be prepared using a carrier that can prevent immediate removal from the body. For example, biodegradable and biocompatible polymers such as ethylene-vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Those skilled in the art can easily prepare these materials. For example, a liposome suspension can also be used as a pharmaceutically acceptable carrier. The liposome can include a lipid composition made of phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE), which can be prepared by preparing a size suitable for use, prepared by a filter of appropriate pore size, and purified by reverse phase evaporation.
[0340] In the present application, the dosage and the number of administrations can be appropriately selected according to the purpose of preventing and / or treating the progression of the disease of the treatment object (subject), the type of disease, the patient's weight, age and other conditions. For example, oral administration can be divided into once or several times a day, or can be administered every few days. In the case of injection, it can be administered continuously or intermittently.
[0341] Reagent test kit
[0342] The kit of the present application may include the drug combination described in the present application. The drug combination may be provided in the form of a kit, and the different components in the drug combination may be packaged in different containers and mixed before administration, or administered separately without mixing.
[0343] For example, separate packaging may be used to allow long-term storage without losing the functionality of the active ingredients.
[0344] For example, the preparation contained in the kit can be present in any type of container in which the preparation components remain active for a long time, are not adsorbed by the container material, and are not easily deteriorated. For example, a sealed glass ampoule, for example, the ampoule can be made of glass, organic polymers such as polycarbonate, polystyrene, ceramics, metals, or any other appropriate materials that can be generally used to hold reagents. In other examples of appropriate containers, simple bottles made of materials similar to ampoules and packaging materials lined with foils such as aluminum or alloys are included. Other containers include test tubes, vials, flasks, bottles, syringes, or the like. The container has a sterile access port for a bottle, etc., and the bottle has a stopper that can be penetrated by a hypodermic injection needle.
[0345] For example, the kit may also include a buffer packaged in the presence of a neutral and non-reactive gas such as nitrogen.
[0346] For example, the kit may also include auxiliary administration devices, such as measuring cups and measuring spoons suitable for oral administration, and syringes, infusion tubes, infusion needles, etc. suitable for injection.
[0347] For example, the kit also includes instructions for use. The instructions for use of the kit consisting of the pharmaceutical composition can be printed on paper or other materials, and / or provided in the form of a medium that can be read electrically or electromagnetically, such as a floppy disk, CD-ROM, DVD-ROM, Zip disk, videotape, audiotape, etc. Detailed instructions for use can be actually attached to the kit, or posted on a website specified by the manufacturer or distributor of the kit or notified by email, etc.
[0348] Without intending to be bound by any theory, the following examples are merely intended to illustrate the drug combination, method and use of treating / preventing cancer, etc. of the present application, and are not intended to limit the scope of the invention of the present application.
[0349] Example
[0350] The drugs used in the examples of the present application can be as shown in Table 1, and can all be obtained through conventional commercial channels.
[0351] Table 1 Drug list
[0352] serial number Drug Name Part Number factory 1 Berberine S9046 Selleck 2 MK0752 T2625 Targetmol 3 RO4929097 S1575 Selleck 4 PF-03084014 S8018 Selleck 5 Vismodegib T2590 Targetmol 6 Sonidegib S2151 Selleck 7 Glasdegib S7160 Selleck 8 LGK974 BD295733-BiDe Pharmaceutical NBW 9 ETC-159 24104 Cayman 11 Foxy-5 HY-P1416A MedChemExpress 12 Sodium Ascorbate S105024 Aladdin
[0353] Among them, the drugs numbered 1-12 were used with DMSO as solvent, and sodium ascorbate was used with PBS as solvent.
[0354] HEK293 cells, HOS human osteosarcoma cells, 143B human osteosarcoma cells, MC38 cells and DB cells in the examples of the present application were purchased from ATCC.
[0355] Example 1 Inhibitory effect of berberine combined with sodium ascorbate on osteosarcoma cells
[0356] 1.1 Cell lines and cell culture
[0357] HEK293 cells, HOS human osteosarcoma cells and 143B human osteosarcoma cells were subcultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS) at 37°C and 5% carbon dioxide in an incubator.
[0358] 1.2 Cell viability assay after single drug administration
[0359] (1) After the cells plated on a 10 cm culture plate have grown to a density of about 90%, remove the culture medium, wash the attached cells with PBS buffer, add 1 mL of trypsin, mix well, and immediately discard. Place in an incubator to digest for about 5 minutes, then add about 10 mL of fresh culture medium and aspirate 10 uL for counting.
[0360] (2) After counting, dilute the cells to a concentration of 1*10 per mL. 5 The diluted cells were plated into a 96-well plate at 100uL per well, i.e., about 10,000 cells per well.
[0361] (3) After the cells were plated in a 96-well plate and cultured for 24 h, berberine was added to the cells at different concentrations, with the gradient being set to six concentrations: 1 μM, 2 μM, 4 μM, 8 μM, 16 μM, and 32 μM.
[0362] (4) 24 hours after drug addition, add 10 μL of CCK-8 solution, incubate in an incubator for 1-2 hours, and use an ELISA reader to measure the absorbance (OD value) of each well at 490 nm and record the results. Calculate the relative cell activity:
[0363] Cell activity = (absorbance of experimental group - absorbance of blank group) / (absorbance of control group - absorbance of blank group) × 100%
[0364] The experimental group is a cell group with different concentrations of drugs added, the control group is a cell group with only solvent (DMSO) added, and the blank group is a group with no cells added but only solvent (DMSO) added. The cell activity results are obtained by the above formula: the cell inhibition rate of the drug = 100% - cell activity. The cell activity of the control group obtained by this formula is 100%. The results of treating cells with berberine at a concentration gradient are shown in Figure 1 shown.
[0365] 1.3 Drug combination cell counting
[0366] (1) After the cells plated on a 10 cm culture plate have grown to a density of about 90%, remove the culture medium, wash the attached cells with PBS buffer, add 1 mL of trypsin, mix well, and immediately discard. Place in an incubator to digest for about 5 minutes, then add about 10 mL of fresh culture medium and aspirate 10 uL for counting.
[0367] (2) Pipette 10uL of the mixed cells into 10uL of trypan blue solution and count.
[0368] (3) After counting, dilute the cells to a concentration of 1*10 per mL. 5 After the diluted cells are mixed, 500uL / well is pipetted into a 24-well plate, i.e., about 50,000 cells per well.
[0369] (4) The cells plated in 24-well plates were cultured for about 24 hours before the drugs were added. The experimental groups included a berberine monotherapy group (concentration of 20 μM), an ascorbic acid group (concentration of 0.5 mM), and a berberine (concentration of 20 μM) and ascorbic acid (concentration of 0.5 mM) combination group. The control group was a cell group to which only the solvent DMSO was added. The blank group was a group to which only the solvent (DMSO) was added but no cells were added.
[0370] (5) 24 h after drug addition, discard the culture medium, add about 150 uL of trypsin and digest for 5 minutes;
[0371] (6) After digestion, add the same amount of PBS to each well and mix well, then add 10uL / well of trypan blue solution and mix well, and take 10uL of the mixed solution to count. Calculate the cell activity of each group according to "cell activity = number of cells in experimental group / number of cells in control group x 100%".
[0372] 1.4 Data Processing
[0373] Data are expressed as mean ± SD, and one-way ANOVA was performed using GraphPad Prism 7.0 software. When P < 0.05, the difference was statistically significant. * indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001, and **** indicates P < 0.0001.
[0374] The coefficient of drug in interaction (CDI) was used to evaluate the interaction between two drugs. The cells were divided into control group, drug A group, drug B group and AB combined drug group, and the cell activities of the three groups A, B and AB were detected respectively.
[0375] CDI = cell activity of group AB / cell activity of group A*cell activity of group B. If CDI is less than 1, it proves that the action of the two drugs is synergistic. When CDI is less than 0.7, the synergistic effect of the two drugs is very significant. If CDI = 1, the action of the two drugs is additive. If CDI is greater than 1, the action of the two drugs is antagonistic.
[0376] Combined results: Under the condition of 20μM berberine alone, the cell activity of HOS cells was 82%, and the cell activity of 143B cells was 94%; under the condition of 0.5mM sodium ascorbate treatment, the cell activity of HOS cells was 106%, and the cell activity of 143B cells was 106%; under the condition of 20μM berberine combined with 0.5mM sodium ascorbate, the cell activity of HOS cells was 29%, and the cell activity of 143B cells was 26%. According to the above CDI calculation formula, the CDI value for HOS cells was 0.33, and the CDI value for 143B cells was 0.26, indicating that the two have a synergistic effect. At the same time, compared with HEK293 cells, the combination of berberine and ascorbic acid can specifically inhibit the activity of 143B cells and HOS cells, and the inhibitory effect on 143B cells and HOS cells is significantly better than that of the corresponding single-drug group (P < 0.001). Results see Figure 2 shown.
[0377] Example 2 Inhibitory effect of Foxy-5 combined with sodium ascorbate on osteosarcoma cells
[0378] The inhibitory effect of Foxy-5 on HOS human osteosarcoma cells and 143B human osteosarcoma cells was detected according to the method of Example 1. The concentration gradient of Foxy-5 and the results of treating cells are shown in Figure 1. Figure 3 shown.
[0379] Combined results: Under the condition of 10μM Foxy-5 monotherapy, the cell activity of HOS cells was 92%, and the cell activity of 143B cells was 71%; under the condition of 0.5mM sodium ascorbate treatment, the cell activity of HOS cells was 103%, and the cell activity of 143B cells was 90%; under the condition of 10μM Foxy-5 combined with 0.5mM sodium ascorbate, the cell activity of HOS cells was 39%, and the cell activity of 143B cells was 47%. According to the above CDI calculation formula, the CDI value for HOS cells was 0.41, and the CDI value for 143B cells was 0.74, indicating that the two have a synergistic effect. At the same time, the inhibitory effect of Foxy-5 combined with ascorbic acid on 143B cells and HOS cells was significantly better than that of the corresponding single-drug group (P < 0.01). Results see Figure 4 shown.
[0380] Example 3 Inhibitory effect of pyrvinium combined with sodium ascorbate on osteosarcoma cells
[0381] The inhibitory effect of Pyrvinium on HOS human osteosarcoma cells was detected according to the method of Example 1.
[0382] Combined results: Under the condition of 0.1μM Pyrvinium alone, the cell activity of HOS cells was 65%; under the condition of 0.5mM sodium ascorbate treatment, the cell activity of HOS cells was 99%; under the condition of 0.1μM Pyrvinium combined with 0.5mM sodium ascorbate, the cell activity of HOS cells was 49%. According to the above CDI calculation formula, the CDI value for HOS cells was 0.76, indicating that the two have a synergistic effect. At the same time, the inhibitory effect of Pyrvinium combined with ascorbic acid on HOS cells was significantly better than that of the corresponding single-drug group (P < 0.05). Results see Figure 5 shown.
[0383] Example 4 Inhibitory effect of niclosamide combined with sodium ascorbate on osteosarcoma cells
[0384] The inhibitory effect of Niclosamide on HOS human osteosarcoma cells and 143B human osteosarcoma cells was detected according to the method of Example 1.
[0385] Combined results: Under the condition of 50μM Niclosamide monotherapy, the cell activity of HOS cells was 56%, and the cell activity of 143B cells was 59%; under the condition of 0.5mM sodium ascorbate treatment, the cell activity of HOS cells was 86%, and the cell activity of 143B cells was 83%; under the condition of 50μM Niclosamide combined with 0.5mM sodium ascorbate, the cell activity of HOS cells was 15%, and the cell activity of 143B cells was 8%. According to the above CDI calculation formula, the CDI value for HOS cells was 0.31, and the CDI value for 143B cells was 0.16, indicating that the two have a synergistic effect. At the same time, the inhibitory effect of Niclosamide combined with ascorbic acid on 143B cells and HOS cells was significantly better than that of the corresponding single-drug group (P < 0.001). Results see Figure 6 shown.
[0386] Example 5 Inhibitory effect of ETC-159 combined with sodium ascorbate on osteosarcoma cells
[0387] The inhibitory effect of ETC-159 on HOS human osteosarcoma cells and 143B human osteosarcoma cells was detected according to the method of Example 1.
[0388] Combined results: Under the condition of 20μM ETC-159 monotherapy, the cell activity of HOS cells was 67%, and the cell activity of 143B cells was 60%; under the condition of 0.5mM sodium ascorbate treatment, the cell activity of HOS cells was 80%, and the cell activity of 143B cells was 77%; under the condition of 20μM ETC-159 combined with 0.5mM sodium ascorbate, the cell activity of HOS cells was 3%, and the cell activity of 143B cells was 7%. According to the above CDI calculation formula, the CDI value for HOS cells was 0.06, and the CDI value for 143B cells was 0.15, indicating that the two have a synergistic effect. At the same time, compared with HEK293 cells, the combination of ETC-159 and ascorbic acid can specifically inhibit the activity of 143B cells and HOS cells, and the inhibitory effects on 143B cells and HOS cells are significantly better than the corresponding single-drug groups (P < 0.001). Results see Figure 7 shown.
[0389] Example 6 Inhibitory effect of LGK974 combined with sodium ascorbate on osteosarcoma cells
[0390] The inhibitory effect of LGK974 on HOS human osteosarcoma cells and 143B human osteosarcoma cells was detected according to the method of Example 1.
[0391] Combined results: Under the condition of 20μM LGK974 monotherapy, the cell activity of HOS cells was 67%, and the cell activity of 143B cells was 64%; under the condition of 0.5mM sodium ascorbate treatment, the cell activity of HOS cells was 87%, and the cell activity of 143B cells was 80%; under the condition of 20μM LGK974 combined with 0.5mM sodium ascorbate, the cell activity of HOS cells was 4%, and the cell activity of 143B cells was 2%. According to the above CDI calculation formula, the CDI value for HOS cells was 0.07, and the CDI value for 143B cells was 0.04, indicating that the two have a synergistic effect. At the same time, the inhibitory effect of LGK974 combined with ascorbic acid on 143B cells and HOS cells was significantly better than that of the corresponding single-drug group (P < 0.001). Results see Figure 8 shown.
[0392] Example 7 Inhibitory effect of Sonidegib combined with sodium ascorbate on osteosarcoma cells
[0393] The inhibitory effect of Sonidegib on HOS human osteosarcoma cells and 143B human osteosarcoma cells was detected according to the method of Example 1. The concentration gradient of Sonidegib and the results of treating cells are shown in Figure 1. Fig. 9 shown.
[0394] Combination results: Under the condition of 10μM Sonidegib monotherapy, the cell activity of HOS cells was 89%, and the cell activity of 143B cells was 74%; under the condition of 0.5mM sodium ascorbate treatment, the cell activity of HOS cells was 106%, and the cell activity of 143B cells was 81%; under the condition of 10μM Sonidegib combined with 0.5mM sodium ascorbate, the cell activity of HOS cells was 62%, and the cell activity of 143B cells was 52%. According to the above CDI calculation formula, the CDI value for HOS cells was 0.66, and the CDI value for 143B cells was 0.87, indicating that the two have a synergistic effect. At the same time, the inhibitory effect of Sonidegib combined with ascorbic acid on 143B cells and HOS cells was significantly better than that of the corresponding single-drug group (P < 0.05). Results see Fig.10 shown.
[0395] Example 8 Inhibitory effect of vismodegib combined with sodium ascorbate on osteosarcoma cells
[0396] The inhibitory effect of Vismodegib on HOS human osteosarcoma cells and 143B human osteosarcoma cells was detected according to the method of Example 1.
[0397] Combination results: Under the condition of 50μM Vismodegib monotherapy, the cell activity of HOS cells was 53%, and the cell activity of 143B cells was 60%; under the condition of 0.5mM sodium ascorbate treatment, the cell activity of HOS cells was 106%, and the cell activity of 143B cells was 82%; under the condition of 50μM Vismodegib combined with 0.5mM sodium ascorbate, the cell activity of HOS cells was 84%, and the cell activity of 143B cells was 13%. According to the above CDI calculation formula, the CDI value for HOS cells was 0.09, and the CDI value for 143B cells was 0.26, indicating that the two have a synergistic effect. At the same time, the inhibitory effect of Vismodegib combined with ascorbic acid on 143B cells and HOS cells was significantly better than that of the corresponding single-drug group (P < 0.001). Results see Fig.11 shown.
[0398] Example 9 Inhibitory effect of PF-03084014 combined with sodium ascorbate on osteosarcoma cells
[0399] The inhibitory effect of PF-03084014 on HOS human osteosarcoma cells was detected according to the method of Example 1. The concentration gradient of PF-03084014 and the results of treating cells are shown in Fig.12 shown.
[0400] Combined results: Under the condition of 10μM PF-03084014 alone, the cell activity of HOS cells was 113%; under the condition of 0.5mM sodium ascorbate treatment, the cell activity of HOS cells was 75%; under the condition of 10μM PF-03084014 combined with 0.5mM sodium ascorbate, the cell activity of HOS cells was 52%. According to the above CDI calculation formula, the CDI value for HOS cells was 0.61, indicating that the two have a synergistic effect. At the same time, the inhibitory effect of PF-03084014 combined with ascorbic acid on HOS cells was significantly better than that of the corresponding single-drug group (P < 0.001). Results see Fig.13 shown.
[0401] Example 10 Inhibitory effect of RO4929097 combined with sodium ascorbate on osteosarcoma cells
[0402] The inhibitory effect of RO4929097 on HOS human osteosarcoma cells and 143B human osteosarcoma cells was detected according to the method of Example 1.
[0403] Combined results: Under the condition of 10μM RO4929097 monotherapy, the cell activity of HOS cells was 56%, and the cell activity of 143B cells was 58%; under the condition of 0.5mM sodium ascorbate treatment, the cell activity of HOS cells was 84%, and the cell activity of 143B cells was 82%; under the condition of 10μM RO4929097 combined with 0.5mM sodium ascorbate, the cell activity of HOS cells was 5%, and the cell activity of 143B cells was 3%. According to the above CDI calculation formula, the CDI value for HOS cells was 0.11, and the CDI value for 143B cells was 0.06, indicating that the two have a synergistic effect. At the same time, the inhibitory effect of RO4929097 combined with ascorbic acid on 143B cells and HOS cells was significantly better than that of the corresponding single-drug group (P < 0.001). Results see Fig.14 shown.
[0404] Example 11 Inhibitory effect of MK0752 combined with sodium ascorbate on osteosarcoma cells
[0405] The inhibitory effect of MK0752 on HOS human osteosarcoma cells and 143B human osteosarcoma cells was detected according to the method of Example 1.
[0406] Combined results: Under the condition of 20μM MK0752 monotherapy, the cell activity of HOS cells was 67%, and the cell activity of 143B cells was 62%; under the condition of 0.5mM sodium ascorbate treatment, the cell activity of HOS cells was 85%, and the cell activity of 143B cells was 80%; under the condition of 20μM MK0752 combined with 0.5mM sodium ascorbate, the cell activity of HOS cells was 3%, and the cell activity of 143B cells was 8%. According to the above CDI calculation formula, the CDI value for HOS cells was 0.05, and the CDI value for 143B cells was 0.16, indicating that the two have a synergistic effect. At the same time, the inhibitory effect of MK0752 combined with ascorbic acid on 143B cells and HOS cells was significantly better than that of the corresponding single-drug group (P < 0.001). Results see Fig.15 shown.
[0407] Example 12 Inhibitory effect of Sulindac combined with sodium ascorbate on osteosarcoma cells
[0408] The inhibitory effect of Sulindac on HOS human osteosarcoma cells was detected according to the method of Example 1. The concentration gradient of Sulindac and the results of treating cells are shown in Fig.16 shown.
[0409] Combined results: Under the condition of 50μM Sulindac monotherapy, the cell activity of HOS cells was 92%; under the condition of 0.5mM sodium ascorbate treatment, the cell activity of HOS cells was 102%; under the condition of 50μM Sulindac combined with 0.5mM sodium ascorbate, the cell activity of HOS cells was 39%. According to the above CDI calculation formula, the CDI value for HOS cells was 0.42, indicating that the two have a synergistic effect. At the same time, the inhibitory effect of Sulindac combined with ascorbic acid on HOS cells was significantly better than that of the corresponding single-drug group (P < 0.05). Results see Fig.17 shown.
[0410] Example 13 Inhibitory effects of different inhibitors combined with sodium ascorbate on colon cancer cells
[0411] According to the method of Example 1, the inhibitory effects of berberine, Foxy-5, Pyrvinium, Niclosamide, ETC-159, LGK974, Sonidigib, Vismodegib, PF-03084014, RO4929097, and MK0752 on colon cancer cells were detected.
[0412] For example, for MC38 colon cancer cells, the control group only added the solvent DMSO, the Nic group added Niclosamide at a concentration of 1 μM, the Vc group added ascorbic acid at a concentration of 0.5 mM, and the Nic+Vc group added Niclosamide at a concentration of 1 μM and ascorbic acid at a concentration of 0.5 mM.
[0413] Fig.18 It is shown that compared with the cell activity of the control group, the cell activity of MC38 cells under the condition of Niclosamide treatment at a concentration of 1 μM is 82%; the cell activity of MC38 cells under the condition of ascorbic acid treatment at a concentration of 0.5 mM is 105%; the cell activity of MC38 cells under the condition of Niclosamide treatment at a concentration of 1 μM and ascorbic acid treatment at a concentration of 0.5 mM is 62%. According to the CDI calculation formula in Example 1, the coefficient of drug in interaction (CDI) for MC38 cells is 0.72, indicating that the two have a synergistic effect. At the same time, the inhibitory effect of Niclosamide combined with ascorbic acid on MC38 cells is better than that of the corresponding single-drug group.
[0414] The results showed that the inhibitory effects of the above-mentioned drugs, such as Wnt signaling pathway inhibitors, combined with sodium ascorbate on colon cancer cells were significantly better than those of the corresponding single-drug groups, and the two had a synergistic effect.
[0415] Example 14 Inhibitory effects of different inhibitors combined with sodium ascorbate on lymphoma cells
[0416] According to the method of Example 1, the inhibitory effects of berberine, Foxy-5, Pyrvinium, Niclosamide, ETC-159, LGK974, Sonidigib, Vismodegib, PF-03084014, RO4929097, MK0752 and Sulindac on lymphoma cells were detected.
[0417] For example, for DB lymphoma cells, the control group only added the solvent DMSO, the Vc group added 2 mM ascorbic acid, the low-dose Nic group added 1 μM Niclosamide, the low-dose Nic+Vc group added 1 μM Niclosamide and 2 mM ascorbic acid, the high-dose Nic group added 2 μM Niclosamide, and the high-dose Nic+Vc group added 2 μM Niclosamide and 2 mM ascorbic acid.
[0418] Fig.19 It is shown that compared with the cell activity of the control group, the cell activity of DB cells under the condition of ascorbic acid treatment at a concentration of 2mM is 76%; the cell activity of DB cells under the condition of Niclosamide treatment at a concentration of 1μM is 57%; the cell activity of DB cells under the condition of Niclosamide treatment at a concentration of 1μM and ascorbic acid treatment at a concentration of 2mM is 17%; the cell activity of DB cells under the condition of Niclosamide treatment at a concentration of 2μM is 52%; the cell activity of DB cells under the condition of Niclosamide treatment at a concentration of 2μM and ascorbic acid treatment at a concentration of 2mM is 15%. According to the CDI calculation formula in Example 1, the drug interaction coefficient for DB cells is obtained, and the CDI value of low-dose Niclosamide combined with ascorbic acid is 0.39, and the CDI value of high-dose Niclosamide combined with ascorbic acid is 0.38, indicating that the two have significant synergistic effects. At the same time, the inhibitory effects of low-dose and high-dose Niclosamide combined with ascorbic acid on DB cells were significantly better than those of the corresponding single-drug groups (P < 0.0001).
[0419] The results showed that the inhibitory effect of the above-mentioned drugs, such as Wnt signaling pathway inhibitors, combined with sodium ascorbate on lymphoma cells was significantly better than that of the corresponding single-drug group, and the two had a synergistic effect.
[0420] The foregoing detailed description is provided by way of explanation and example and is not intended to limit the scope of the appended claims. Various changes to the embodiments currently listed in this application are obvious to those of ordinary skill in the art and are retained within the scope of the appended claims and their equivalents.
Claims
1. Use of a combination of a preventively and / or therapeutically effective amount of ascorbic acid or a pharmaceutically acceptable ascorbate thereof and a preventively and / or therapeutically effective amount of a second therapeutic agent in the preparation of a medicament for preventing and / or treating tumors, wherein the second therapeutic agent is a Notch signaling pathway inhibitor, and the Notch signaling pathway inhibitor is MK0752, RO4929097 or PF-03084014, and the medicament is configured to be administered in the following effective amount ratio: the effective amount molar ratio of MK0752 to ascorbic acid or a pharmaceutically acceptable ascorbate thereof is 1:25, the effective amount molar ratio of RO4929097 to ascorbic acid or a pharmaceutically acceptable ascorbate thereof is 1:50, and the effective amount molar ratio of PF-03084014 to ascorbic acid or a pharmaceutically acceptable ascorbate thereof is 1:50; and the tumor is osteosarcoma.
2. The use according to claim 1, wherein the pharmaceutically acceptable ascorbate comprises sodium ascorbate.
3. The use according to claim 1, wherein the second therapeutic agent and the ascorbic acid or a pharmaceutically acceptable ascorbate thereof are configured to be administered to the subject simultaneously.
4. The use according to claim 1, wherein the second therapeutic agent and the ascorbic acid or a pharmaceutically acceptable ascorbate thereof are formulated to be administered separately to a subject.
5. The use according to claim 1, wherein the medicament is formulated such that the second therapeutic agent is administered at a dose of 1 mg / kg to 100 mg / kg.
6. The use according to claim 1, wherein the medicament is formulated so that the ascorbic acid or a pharmaceutically acceptable ascorbate thereof is administered at a dose of 0.05 g / kg to 2.5 g / kg.
